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1. Introduction
This thesis describes several studies, which illustrate the physiology
and pathophysiology of growth hormone. This chapter provides an
overview of the concepts underlaying the studies.
1.1 Regulation of growth hormone secretion
Growth hormone (GH) is synthesized in the anterior pituitary gland by
somatotropic cells. This gland is situated within the bony sella turcica
and is overlain by the dural diaphragma sella, through which the stalk
connects to the hypothalamus. Most of the functioning anterior pituitary
cells consist of somatotroph cells (35-45 %)(1). In recent years, much
knowledge has emerged on the embryogenesis of the pituitary. It has
been discovered that the differentiation of pituitary stem cells into
somatotroph cells is regulated by two transcription factors, PROP-1
and Pit-1 (2;3), which has clinical relevance for the understanding of
congenital GH deficiency syndromes.
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The two most important regulators of GH secretion are the hypothalamic
peptides Growth Hormone Releasing Hormone (GHRH) and
Somatostatin. Both hypothalamic peptides are secreted in independent
waves and interact together to generate, and control, GH release. GHRH
stimulates GH release, whereas somatostatin has an inhibitory effect.
After GHRH is secreted by the hypothalamus, it is transported through
the portal system to the somatotroph cells, where it binds to the GHRH
receptor (1;4). Stimulation of the GHRH receptor results in the release
of presynthesized GH, that is stored within the cells. In contrast to the
GHRH receptor, of which no receptor subtypes are known, 5 different
somatostatin receptor subtypes can be distinghuished. In the pituitary
gland, the 2 most important somatostatin receptor subtypes are the
subtypes 2 and 5 (5). After binding of somatostatin to its receptor,
somatostatin inhibits GH secretion and/or cell proliferation (6).
In addition to the effects on the pituitary with respect to the release of
GH, somatostatin and GHRH influence each others release. GHRH
stimulates somatostatin secretion, whereas somatostatin inhibits GHRH
secretion (4). The integrated effect of GHRH and somatostatin on the
pituitary gland ultimately leads to GH secretion. This is characterized
by a pulsatile pattern with high amplitude pulses, especially at night,
and low amplitude pulses  predominantly during daytime.
GH secretion is regulated in a feedback system. The most important
peptide in this system is Insulin-like-Growth factor I (IGF-I). Plasma
IGF-I is predominantly produced  by the liver, whereas IGF-I synthesis
occurs in virtually all tissues and acts in a paracrine fashion. Most
circulating IGF-I is bound to IGF-binding protein 3 (IGF-BP3) and acid
labile sub unit (ALS). IGF-I is transported to the brain, where it has
numerous effects. The most important action of IGF-1 in the brain is
the stimulation of somatostatin  production, which will eventually reduce
GH production (7).
In addition to these important regulators of GH secretion, recently a
novel potent GH secretagogue has been discovered, Ghrelin (1). Ghrelin
appears to be the natural ligand of the growth hormone secretagogue
receptor (GHS-R). Activation of this receptor by Ghrelin leads to potent
GH secretion.
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Ghrelin is predominantly produced by the stomach and released into
the bloodstream. In addition to the GH releasing activity, it also
stimulates the release of other pituitary hormones like cortisol and
prolactin and plays a role in stimulating appetite, controling energy
balance and gastric motility. Although Ghrelin is a potent GH releasing
peptide, recent insight indicates that Ghrelin contributes more to the
regulation of diverse functions of the gut-brain axis than to GH secretion
per se (8).
1.2   GH and IGF-I
GH binds membrane-anchored GH receptors(9). The extra-cellular
domain of this receptor can be released into the circulation and is referred
to as growth hormone binding protein (GHBP), which may serve as a
stabilizer of GH availability in the circulation (10). GH receptors are
found in many peripheral tissues, especially in the liver. After binding
of GH to the GH receptor, the receptor initiates a phosphorylation cascade
involving a JAK/STAT pathway, which is ultimately leads to the
biological actions of GH (11;12).
In general, GH acts on peripheral tissues by two mechanisms: 1) a direct
effect, and 2) an indirect effect via IGF-I, produced, and secreted into
the blood, by the liver or produced locally within a certain tissue. Of the
circulating IGF-I, approximately 75 % is produced in the liver, the
remainder being produced locally (13). IGF-I binds to the IGF-I receptor,
which results in tyrosine phosphorylation to initiate its effect (14).
1.3      Physiological effects of GH
The physiological actions of GH involve many organs and physiological
systems. Although a  complete overview of GH action falls beyond the
scope of this chapter, important effects include longitudional bone
growth, metabolism and - relevant for the scope of this thesis - the heart
and general well-being.
GH plays an important role, through IGF-I dependent processes, in
postnatal longitudinal bone growth and remodelling by inducing
proliferation or/and differentiation of chondrocytes, osteoblasts,
osteoclasts and collagen type I synthesis (15-18). In addition to bone
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remodelling, IGF-I increases the fiber content and strength of skeletal
muscles (19).
GH exerts many metabolic effects that persist throughout life. GH has a
lipolytic effect in fat and muscle. After acute administration of GH, a
rise in circulating free fatty acids (FFA) and glycerol is observed (20;21).
Moreover, a reduction of LDL and elevations of HDL levels is observed
with GH administration (22). Acute administration of GH causes a
temporary effect on glucose uptake similar to insulin, whereas chronic
GH administration leads to insulin resistance with hyperinsulinemia,
due to a post receptor defect in insulin signaling (23). These effects
may be partially explained by GH induced lipolysis and elevated plasma
FFA, that inhibit insulin activity at its target tissues. GH therapy also
increases lean body mass by enhancing protein synthesis, with a small
inhibiting effect of protein degradation (24).
In addition to these metabolic effects, GH plays a role in
immunomodulation, like B and T- cell proliferation, macrophage activity,
immunoglobulin production etc. Therefore, GH exerts pleiotropic effects
in many physiological systems. Remarkably, however, these effects are
in general very subtle in adult patients and cannot be easily quantified
by clinicometric approaches. This is probably the reason, that, in general,
there is a long delay between the start of the disease acromegaly and the
time of diagnosis (see below). In addition, the effects of GH substitution
on GH deficient patients exemplify these subtle effects.
1.4       GH and the heart
The GH - IGF-I axis plays an important role in cardiac development
and function. In cardiomyocytes both GH and IGF-I receptors are
expressed (25). Interestingly, the GH receptor gene is expressed to a
greater extent in the myocardium than in many other tissues (26). In
hypophysectomized rats, GH induces cardiac IGF-I mRNA expression
and increases cardiac IGF-I content. In turn, IGF-I increases the size of
cultured cardiomyocytes and enhances myofibril development (27).
Concomitantly, IGF-I down regulates sms-actin, a protein that forms
stress fiber-like structures (28). GH and IGF-I have a direct effect on
myocardial contractility. By increasing the intracellular calcium content
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and enhancing the calcium sensitivity of myofilaments in
cardiomyocytes, GH and IGF-I promote the contractility of the
myocardium (29;30). Thus, it appears that GH and IGF-I have positive
inotropic effects on the heart by increasing cardiac growth and by
increasing the sensitivity of the myofilament apparatus to Ca 2+ .
1.5 GH and quality of life
As discused above, GH has effects in almost every organ system. These
effects are translated in a subtle way into quality of life. Many studies
on GH deficient subjects have shown that GH deficiency leads to
impaired quality of life (31-33). In most studies, restoration of GH levels
improves  quality of life in the majority of the patients (34). GH may act
directly or indirectly on neural sites. In the human hippocampus,
putamen, thalamus, hypothalamus and pituitary, GH receptors are found,
suggesting a direct role of GH in the brain (35;36). The hippocampus
may be important with respect to neural effects of GH as this region
plays an important role in memory, motivation and attention (37). The
mechanism whereby GH exerts direct effects on psychological functions,
is largely unresolved (38;39).
GH may enhance cognition by stimulating brain growth and
development. Studies in GH deficient mice have shown impaired brain
growth, glial and neuronal proliferation, and myelinisation. Conversely,
brain size is increased in GH transgenic mice (37). Accordingly, GH
plays an important role in neural function during brain injury. Studies
in rats have shown that GH can prevent cell loss in the hippocampus
(40), following hypoxic/ischemic injury. GH enhances cerebral blood
flow and intracellular communication and, which improves neural
function (41;42).
GH may be involved in normal sleep generation. In GH deficient patients
decreased deep sleep, increased total sleep time and a decreased REM
sleep have been observed, which could be reversed by restoration of
GH levels (43;44).  Nonetheless, the importance of GH in sleep
generation has been questioned by other authors (45;46).
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1.6 Pathophysiolocal effects of GH: GH excess
Acromegaly is a rare disorder of GH excess, first described by Pierre
Marie in 1886. This syndrome is characterized by elevated GH and
IGF-I levels and by progressive somatic disfigurement and systemic
manifestations. The prevalence is currently approximately 40 cases per
million subjects with an estimated annual incidence of three to four
patients per million subjects (47-49).
In almost all cases, GH excess is caused by a GH  secreting pituitary
adenoma. In very rare cases, the syndrome is caused by extra-pituitary
production of GH or GHRH in neuroendocrine tumors, like carcinoid
tumors (50).

Acromegaly is a disease that develops slowly, with only little and subtle
clinical symptoms in the beginning (see Figure 1). Therefore, there is
an average delay of 8 years in the diagnosis of acromegaly. At the time
of diagnosis patients have coarsened facial features, soft tissue
hypertrophy and exaggerated growth of hands and feet. Other
characteristics consist of an increased number of skin tags, sleep apnoe,
colonic polyps, insulin resistance, carpal tunnel syndrome and
Fig. 1 Clinical features of acromegaly
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cardiovascular disease like hypertension and cardiac hypertrophy (50-
52).
The treatment of first choice is still trans-sphenoidal surgery, with success
percentages ranging 60-70 % on the short term (53-56). The success of
surgery depends on the skill and experience of the surgeon. Side effects
of the surgical procedure are related to the size of the tumor and on the
invasiveness of the tumor into adjacent structures. The most important
side effects are hypopituitarism and permanent diabetes insipidus (57).
Meningitis is a direct and serious surgical complication. After a follow
up of more than 10 years, recurrences occur in 19 % of the patients,
resulting in a 10 year cure rate of only 40 % (55). Therefore, adjuvant
treatment is necessary in many patients to treat persistent or recurrent
disease.
The first choice of adjuvant therapy is medical therapy. Current medical
treatment options are mostly based on the fact that somatotroph
adenomas express high levels of somatostatin receptors subtypes 2 and
5 (58;59).  By stimulating these receptors, GH secretion will be
suppressed, leading to decreased IGF-I levels. Two long-acting
somatostatin analogues, octreotide and lanreotide, are currently available,
which have a high binding affinity to somatostatin receptor subtype 2
and to a lesser extent subtype 5 (5). With the introduction of the octreotide
long acting repeatable (LAR) formulation, patients only require an
intramuscularly injection once monthly. In approximately 60 % of the
patients octreotide treatment decreases GH levels beneath 2.5 µg/L and
normalizes IGF-I levels (60;61).
In clinical practice, octreotide LAR appeared to be more effective in
suppressing GH secretion than the slow release (SR) preparation of
lanreotide (62-65). Lanreotide (SR) had to be injected every 2-3 weeks
and effectively controlled GH and IGF-I levels in fewer patients.
Recently, a new slow release depot preparation of lanreotide was
introduced, Lanreotide Autogel (66). This new depot formula of
lanreotide has to be injected subcutaneously only once a month. Chapter
2 of this thesis describes a prospective study in which the efficacy of
octreotide LAR and lanreotide Autogel in suppressing GH and IGF-I
levels was compared in patients with active acromegaly.
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Another new perspective in somatostatin analogue treatment is the
development of SOM 230 (67). This novel drug has a broader binding
affinity for somatostatin receptor subtypes. Compared with octreotide
it has higher binding affinity to somatostatin receptor subtype 5, and to
a lesser extent also to somatostatin receptor subtypes 1 and 4 (5;68).
Preliminary data are promising, but further investigations are needed to
establish the additional value of this new drug in the treatment of
acromegaly (69).
In the development of drugs aimed at decreasing GH levels in
acromegalic patients, recently a new approach was introduced.
Pegvisomant is a competitive inhibitor of the GH receptor.  Pegvisomant
is highly effective and normalizes IGF-I levels in 97% of the patients
(70;71). One of the concerns of this new drug is that by blocking the
GH receptor the patient may become GH deficient. The clinical value
of this drug in acromegaly has therefore to be studied in long-term studies
(72). Currently, Pegvisomant is used in patients who do not effectively
respond to treatment with somatostatin analogues.
The last therapeutical option in acromegaly is the use of radiotherapy.
Although effective in reducing GH secretion, the response is slow and
takes many years (73). After 6 years, 70% of the patients have normal
IGF-I levels, whereas after 10 years, 10-15 % of the patients still have
high levels of GH (73;74). One of the major side effects of radiotherapy
is hypopituitarism, which develops in almost 55 % of the patients after
10 years (75). Lethargy, impaired cognitive function and personality
changes are also observed in patients who were treated with radiotherapy
(76). Therefore radiotherapy is currently used as an adjuvant therapy in
acromegaly only when surgical and/or medical therapy have failed.
The goal of therapy in acromegaly is biochemical cure (according to
consensus defined as GH levels below 2.5 µg/L (or 5 mU/L) and IGF-
I levels in the normal age and sex adjusted range. These criteria are
based on historical outcome parameters of therapy in acromegaly:
Mortality risk normalizes when these treatment goals ar reached
(53;77;78). The morbidity that accompanies acromegaly, like impaired
glucose tolerance, an adverse lipid profile, sleeping disorders and
acromegalic arthropathy (e.g. osteoartrithitis, cartilage thickness)
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improves, when effective treatment is instituted. Also the cardiac
abnormalities observed in active acromegaly, like biventricular-
concentric hypertrophy, diastolic dysfunction at rest, systolic dysfunction
at exercise and diastolic heart failure improve or normalize after curation
(26;79-81). The above defined biochemical criteria for cure are
supported by a recent study that showed that GH secretion in cured
acromegalic patients assessed by with detailed 24-hour GH secretion
profile did not differ from normal subjects (82).
Patients, in whom the biochemical treatment goals can only be reached
by continuous treatment with medicial therapy, have so called well-
controlled disease. Studies have shown that morbidity in these well
controlled patients improves to the same extent as in cured acromegalic
patients: after 12 months of somatostatin therapy, a decrease in left
ventricular mass, an improvement in diastolic function and - to a lesser
extent - systolic function is observed (51), despite the fact that 24-hour
GH secretion is not completely restored like in cured acromegalic
patients (83). The question, therefore, remains, whether these patients
still have persisting subtle effects of GH overproduction.
Moreover, most studies investigating the effect of treatment on cardiac
function in acromegaly used heterogeneous groups, including de novo
acromegaly patients in combination with uncontrolled treated patients,
or well-controlled patients in combination with cured patients for
analyses (81;84-89). One study used a homogenous group of patients
(90), but did not include all relevant diastolic and systolic parameters.
In Chapter 3 it is investigated whether cardiac function in well-
controlled acromegalic patients is really normalized as compared with
cured patients, using 2 dimensional echocardiography, as well as Tissue
Doppler echography, which allows detailed measurement of diastolic
function.
A remarkable lack in the knowledge on cardiac consequences of
acromegaly is that despite the many investigations on cardiac function
in these patients, (26;51;79;80;91-93) little is known about cardiac valve
function. It is known that GH excess changes the cardiac structure and
diastolic function in acromegalic patients. It is also known that GH
excess affects the composition and structure of collagenous tissue in
18
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general. Heart valves consist mainly of collagen but it is has not been
documented whether GH excess has any effect on cardiac valves.
Chapter 4 addresses this issue in different groups of acromegalic
patients.
1.7 Pathophysiological effects of GH: GH deficiency
GH deficiency occurs when the pituitary secretes an insufficient amount
of GH levels. This occurs in congenital pituitary deficiencies, like a Pit-
1 or PROP-1 mutation, or in macroadenoma of the pituitary, (e.g. non-
functional adenoma), or through other factors that damage the pituitary
and/or hypothalamus (e.g. trans-sphenoidal surgery, or irradiation).
Interestingly, disturbances in the GH-IGF-I axis can also occur in patients
with a normal hypothalamus/pituitary axis but with a chronic disease,
e.g. chronic heart failure or obesity.
Patients with adult-onset GH deficiency have many signs and symptoms
(Table 2). GH deficiency is associated with a twofold increased risk of
death from cardiovascular disease as compared with healthy controls
(94-98). The high cardiovascular mortality risk is associated with an
favourable metabolioc profile (abdominal obesity, insulin resistance,
an abnormal lipid profile, atherosclerosis, endothelial dysfunction and
hypercoagulability) and abnormal cardiac function (decreased cardiac
function, with reduced left ventricular mass, left ventricular diameters
resulting in an impaired systolic function at exercise). Other
abnormalities are reduced pulmonary function, muscle dysfunction and
decreased performance capacity (80;93;99-104).
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Table 2. GH deficiency: Signs and symptoms (ref.108)
The introduction of recombinant human GH (rhGH) has been an
important development for the treatment of GH deficiency. RhGH
therapy restores IGF-I levels into the normal range (105;106). However,
physiogical GH profiles cannot be restored, as GH levels after rhGH
administration follow a pharmacological pattern with a T max of 2-4
hours with a slightly down slope GH level during 24 hour (107).
Restoration of normal IGF-I levels, and to a lesser extent GH levels,
result in an improvement of many organ functions, including insulin
tolerance, lean body mass, lipid metabolism, exercise tolerance, bone
mass, and cardiac function (102;108-110). When rhGH was introduced
as a treatment for adult GH deficiency, studies suggested that quality of
life (QoL) also improved. However, all these studies were limited with
respect to the fact, that they only focussed on one dimension of QoL
(see the review of Hull et al. (34)). There are only a few studies that
studied different aspects of QoL, like depression and general well being
20
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(114-116) . In addition, most studies investigated QoL in GH deficiency
patients before and after rhGH administration, but did not compare QoL
with healthy subjects (114). Chapter 5 will address the QoL in GHD
patients on long-term treatment with rhGH as compared to healthy
subjects.
In patients with panhypopituitarism currently not all deficient hormones
are replaced. The adrenal cortex produces more hormones than cortisol,
which is the only adrenal hormone that is  substituted in patients with
ACTH insufficiency. One of the key products of the adrenal gland is the
hormone DHEA (di-hydro-epi-androsterone) and its sulfate DHEA-S,
from which many other steroid hormones are synthesized through
intracrine pathways (117;118). Using DHEA replacement in patients
with primary adrenal insufficiency, an improvement in quality of life,
and sexual functioning was observed (119-121). Interestingly, some
studies also showed, that DHEA replacement increased IGF-I levels
(120;122-124). It was unclear, however, whether the increase in IGF-I
levels was due to altered GH secretion and/or to an effect of DHEA on
IGF-I production. We hypothesized that patients with secondary adrenal
insufficiency will benefit of DHEA replacement, and that the increase
of IGF-I could play a role in this improvement. In chapter 5 the effect
of DHEA replacement on QoL and IGF-I will be described in GH and
ACTH deficient patients, treated with a fixed dose of rhGH.
In patients with alterations in the GH-IGF-I axis, like chronic non-
endocrine disease, or even elderly subjects, the idea emerged that
restoration of GH levels would benefit the patients. In line with this
assumption, studies performed in the early nineties suggested that
patients with idiopathic dilated cardiomyopathy or ischemic cardiac
failure would benefit from the positive effects of GH on cardiac muscle
(125;126). The idea was, that by improving the strength of the cardiac
muscle cardiac function improves. Studies indeed showed promising
results, but most studies were only observational. Randomised
(controlled) studies could not confirm the results (127-129). These
studies mainly focused on the systolic function, although the majority
of patients with cardiac failure have diastolic dysfunction (130).
Therefore, in chapter 6, the effect of rhGH in ischemic cardiomyopathy
21
General introduction
on cardiac function with special focus on diastolic function is described.
1.8         Aims of this thesis
GH plays an important role in the human body, by direct and/or indirect
mechanisms. The aim of this thesis is to focus on different clinical aspects
of the physiological role of GH in humans, with a special focus on three
different models. The first model is the model of GH excess: acromegaly.
In this model we compared the effects of two somatostatin analogues
on GH secretion, the effect of the treatment of acromegaly on cardiac
function and on cardiac valves. In the second model, GH deficiency,
the investigations focused on the effects of DHEA replacement on quality
of life and IGF-I concentrations. The third and last model is the model
of relative GH deficiency in a chronic non-endocrine disease (ischemic
cardiomyopathy), where we tested the hypothesis that restoring GH
levels could have beneficial effects on cardiac function.
In chapter 2 data are presented of a comparison between a new depot
somatostatin analogue, Lanreotide Autogel, and the only other available
depot preparation, Octreotide LAR. Lanreotide Autogel is a new slow-
release depot preparation that requires monthly injections. To compare
the two medications in effectively suppressing GH levels, seven patients
were first analysed during treatment with octreotide LAR before they
were analysed on the new drug. The effects of GH suppression was
analysed with two different approaches. First using GH profiles (an
average of GH levels taken every 30 minutes for 3,5 hour) assessed 2, 4
and 6 weeks after an injection. Secondly, we compared GH secretion
characteristics in detail via deconvolution analysis of 24 h plasma GH
concentration profiles.
Chapter 3 presents data of cardiac function in patients with so-called
well-controlled acromegaly during treatment with somatostatin
analogues compared with other therapeutic modalities. One of the
remarkable observations presented in chapter 2 is that although patients
are well controlled by somatostatin analogues according to strict
biochemical criteria, the total 24-hour GH production remains relatively
22
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high, in comparison to acromegalic patients cured by surgery, who
exhibit normal 24 GH secretion. It is uncertain, whether this difference
in GH levels translates into biological effects. A sensitive organ that
reacts to GH excess is the heart. Therefore, de novo, active and well-
controlled patients, as well as cured acromegalic patients, underwent
echocardiography to compare systolic and diastolic function in detail.
Although there are many studies that assessed cardiac function in
acromegaly patients, this is the first study in which diastolic and systolic
functions in the four categories of therapeutic modalities were compared
with each other.
Chapter 4 presents data of an observational study on the prevalence of
myocardial valve dysfunction in acromegaly. Despite some case reports,
the prevalence or incidence of valvular insufficiency has not been
documented in acromegalic patients. To investigate the effects of active
acromegaly on valvular insufficiency both active (de novo and treated
active patients) and inactive (cured and well-controlled) patients were
investigated.
In chapter 5 the results of a double-blind, placebo controlled randomised
cross-over study are presented. In this study the effects of DHEA on
IGF-I and QoL were investigated in patients with GH deficiency and
secondary adrenal failure, who were on stable hormone substitution.
Any difference in QoL, measured with a broad spectrum of parameters,
was assessed. Together with a general test (SF-36), the effects on
depression, and anxiety (HADS), fatigue (MFI-20) and sexual
functioning were investigated.
In chapter 6 the data are presented of a randomised study in which
rhGH in a fixed dose was given for 6 months to patients with ischemic
cardiac failure. At baseline and after 6 months cardiac function was
assessed using MR cardiac imaging. The goal was to investigate the
change in systolic and diastolic function after rhGH therapy, as was
suggested in a few studies with patients with dilated cardiomyopathy.
23
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In chapter 7 the data of the studies presented in this thesis are
summarized and discussed.
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Abstract
Objective Recently a new depot preparation of the long-acting
somatostatin analogue, lanreotide Autogel was introduced for the
treatment of acromegaly. Like octreotide long-acting repeatable (LAR),
it has high binding affinity for the somatostatin receptor subtype SSTR
2 and less binding affinity for SSTR 5. We hypothesized that the ability
to suppress GH secretion in patients with acromegaly would be similar
for these depot preparations.
Patients and study design Seven patients (mean age 48.4 – 7 yr) on
long-term octreotide LAR treatment at a monthly injection interval for
a mean of 2.8 yr were enrolled in the study. They underwent a GH
secretory profile study with 10 min sampling for 24 hr, 28 days after an
injection. At two, four and six weeks after the next injection fasting GH
profiles (every 30 min for 3.5 hours) and serum IGF-I  measurements
were measured. These investigations were repeated 12 months later,
when the patients were on an individually titrated stable dose of
lanreotide Autogel.
Results Secretory characteristics and total 24 h GH secretion, estimated
by deconvolution analysis of the 10 min 24 h plasma GH concentrations,
did not show differences between these two long-acting somatostatin
analogues. Both drugs were equally effective in GH and IGF-I
suppression as measured at 2, 4 and also at 6 weeks following an
injection.
Conclusion The efficacy of lanreotide Autogel and octreotide LAR was
equal, notwithstanding that these drugs are administered in a different
way and have different pharmacokinetics.
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Introduction
Acromegaly is a syndrome caused by overproduction of growth hormone
(GH) from a GH-secreting pituitary adenoma. The high levels of GH
and IGF-I are associated with increased morbidity and mortality, which
necessitates adequate control of the disease (1,2). Although
transsphenoidal microsurgery is the first choice treatment in eligible
patients, somatostatin analogues are the preferred secondary therapy in
the 30-40 % of patients not in remission after surgery and in the 10-15
% who develop recurrence of disease during long-term follow-up(1,3,4).
Furthermore, primary treatment of acromegaly with somatostatin
analogues is increasingly applied (5).
Somatotrope adenomas express high levels of somatostatin receptor
subtypes SSTR 2 and 5 (6,7). The somatostatin analogues octreotide
(Novartis Pharma AG, Basel Switzerland) and lanreotide (Ipsen Biotech,
Paris, France) both have high binding affinity for the SSTR 2 and to a
lesser extent for the SSTR 5 (8). Octreotide LAR, the depot preparation
of octreotide given by monthly i.m. injections is able to normalize GH
concentrations in 56% and IGF-1 in 66% of the patients (9). Lanreotide
Slow Release (SR), the more frequently i.m. injected depot preparation
of lanreotide, seems less effective in normalizing GH and IGF-I
concentration (10-13). Recently, lanreotide Autogel, a new slow-release
depot preparation of lanreotide was introduced. This new delivery
formulation is available in small-volume, prefilled syringes, and is
administrated by monthly deep s.c. injections (14).
Considering the comparable binding affinity of octreotide and lanreotide
for SSTRs, we hypothesized that there would be no difference between
the two depot preparations in their ability to suppress GH secretion in
patients with acromegaly. To test this hypothesis, we applied two
different independent approaches: first by measuring GH secretion
characteristics via deconvolution analysis of 24 h plasma GH
concentrations profiles. We have recently shown that sustained blockade
by octreotide can not restore all these parameters of abnormal GH
secretion, but we have not established that for lanreotide (15).  Secondly,
we evaluated the extent and duration to which both depot somatostatin
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analogues suppressed GH and IGF-I secretion.
Methods
Patients
For this study we included 7 patients with active acromegaly (of whom
two were studied previously), who showed relatively good
responsiveness to octreotide(15). The diagnosis was based on the
characteristic clinical features and confirmed by insufficient suppression
of GH concentration during the glucose tolerance test, the presence of a
pituitary adenoma on radiological imaging,  and elevated age-adjusted
IGF-I concentrations. The clinical characteristics of the patients are
described in Table 1. All patients used octreotide LAR (20 or 30 mg, at
a monthly scheme) for an average duration of 2.8 years. None of the
patients received a dopamine agonist before or during the study.
Although the treatment goals were similar for both analogues, i.e. GH
< 5 mU/L and a normal age-related IGF-I, four out of seven patients
were using 20 mg of octreotide LAR, whereas six patients required the
highest dose (120 mg) of lanreotide. The patients were first titrated on
octreotide LAR. When there was a discrepancy between GH and IGF-I
concentrations we gave preference to IGF-I, at least when the clinical
response was satisfactory. The resultant octreotide LAR dose required
was 20 mg in four,  and 30 mg in three patients. Three out of four
patients already had reached the treatment goals, and the fourth patient
did not have better results on 30 mg octreotide LAR.
The local Medical Ethical Committee approved the protocol and all
patients gave written informed consent.
Study protocol (Figure 1)
The patients were investigated in a prospective study design according
to the following protocol. The patients were first analysed on their regular
octreotide LAR treatment. To assess details of GH secretory
characteristics during chronic octreotide treatment, a 24 h plasma GH
profile (with 10 min intervals) was performed 4 weeks after an octreotide
LAR injection. To assess the extent and duration of GH suppression
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during chronic treatment fasting morning GH profiles were obtained at
2, 4 and 6 weeks after the last octreotide LAR injection. Subsequently,
patients were included in a Phase II International Multicentre Trial for
Evaluating the Efficacy and Safety of Lanreotide Autogel (Data on file
Ipsen Beaufort, study E2852030717). Patients were randomised to
receive 60, 90, or 120 mg of lanreotide Autogel, the dose of which was
subsequently adjusted according to individual fasting GH profiles and
IGF-I concentrations during the course of the trial aiming at a serum
GH concentration < 5mU/L and a normal IGF-1 for age. Six of the
seven patients required the highest lanreotide dose. At the end of the
international trial, one year later, the investigations were repeated, i.e. a
24 h plasma GH profile 4 weeks after a lanreotide Autogel injection
followed by a GH profile 2, 4 and 6 weeks after an injection. Radiological
imaging (MRI or CT scan) of the pituitary was performed before the
start on each analogue and twice during follow up.
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Figure 1. Study protocol.
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Study parameters
24 hours GH profile
 Patients were hospitalised the evening before the sampling studies, 27
days after the last injection with octreotide LAR or lanreotide Autogel.
The following morning, an intravenous cannula was inserted into a large
forearm vein, and blood samples were withdrawn at 10-min intervals
for the next 24 h, starting at 9.00 h. Standard meals were served at
predetermined time points, 7.30 h, 11.30 h and 17.30 h. Lights were
turned off between 22.00 h and  07.00 h. All plasma samples were frozen
immediately and stored at 20 0  C until analysis.
Short-withdrawal study
After an overnight fast, patients were admitted to the Clinical Research
Centre of the Department of Endocrinology between 08.00 and 09.00
h. An intravenous catheter was inserted in a forearm vein for collection
of all blood samples. The patients were fasting during the blood sampling
procedure. From the first blood sample plasma IGF-I concentration was
determined. Subsequently, blood samples were obtained every thirty
minutes for 3.5 hours. The mean GH was calculated from 8 samples.
All samples from the patients were stored at  20 0 C until analysis in
the same GH and IGF-I assay runs.
Assays
GH concentrations were measured with a sensitive time-resolved fluoro-
immunoassay (Wallac, Turku, Finland) specific for the 22-kDa GH. The
standard was recombinant human GH (Genotropin, KabiVitrium,
Uppsala, Sweden), which was calibrated against the WHO First
International Reference Preparation 80/505. To convert mU/L to µg/L,
divide by 2.6). The limit of detection (defined as the value 2 SD above
the mean value of the zero standard) was 0.03 mU/L. The intra-assay
coefficient of variation (CV) ranged from 1.6 to 8.4 % in the assay
range between 0.26-47 mU/L, with corresponding inter-assay CVs of
2.0 9.9 %. The total serum IGF-I concentration was measured by IRMA
after dissociation and blocking of the IGF-binding proteins with IGF-
40
Chapter 2
II. (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). The
references values ( 95 % CI) per decade  ranged form 11-77 nmol/l for
20 - 30 yrs, 10 - 42 nmol/l for 30 - 40 yrs, 8  33 nmol/l for 40-50 yrs, 8-
24 nmol/l for 50-60 yrs and 8-22 nmol/l for 60-70 yrs.
Analytical techniques
Multiparameter deconvolution analysis was used to quantitate basal GH
secretion and the GH half-life (16). This waveform-specific technique
estimates the rate of basal release, the number and mass of randomly
ordered secretory bursts, and the subject-specific (mono-exponential)
half- life (17). The daily secretion rate is the product of secretory burst
frequency and mean mass of GH released per event. Total GH secretion
is the sum of basal and pulsatile secretion (16).(17)
Statistical Analysis
Data are given as the mean – SEM, unless otherwise noted. Statistical
analysis were carried out using Students t-test when applicable and
with multivariate repeat measures analysis to compare differences
between and within groups. Calculations were performed with SPSS
for Windows version 11.0 (SPSS Inc., Chicago, IL). P < 0.05 was
considered significant.
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Results
All patients completed the study. Chronic treatment with lanreotide
Autogel was well tolerated by all patients, as was octreotide LAR
treatment. Three patients experienced bowel cramps and diarrhoea for
several days after the first injections of lanreotide Autogel, resolving
after the fourth injection.  No adverse events were reported during the
study.
Of the three patients who had previous surgery, no change in residual
tumor volume was noted  on both analogues. In one out of four non-
operated patients, a 50%  decrease in tumor volume was found  during
octreotide LAR treatment, but no further change in tumor volume could
be detected in these patients during subsequent lanreotide treatment.
24 hour plasma GH Profile
Fig.1 describes the 24 h plasma GH concentrations of all seven patients
during treatment with both somatostatin analogues, showing a
remarkable similar pattern. The secretory characteristics as analysed by
deconvolution analysis were similar during both treatments  and are
detailed  in Table 2. The pulsatile and total GH secretion per 24 h were
not different between octreotide LAR and lanreotide Autogel.
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Table 1. Patient characteristics of 7 patients studied during chronic
octreotide LAR and lanreotide Autogel therapy.
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Short withdrawal study
Table 3 describes the mean GH levels and IGF-I concentrations during
the 6 weeks of withdrawal. Mean GH and IGF-I levels obtained 2, 4,
and 6 weeks were not different between the two treatment groups. In
time, no significant changes in GH levels and IGF-I concentrations could
be detected within the two treatments.
The number of patients achieving both control of GH and IGF-1 were
three under both treatment modalities. In only one patient of the
remaining four, GH was normal on octreotide and slightly elevated on
lanreotide, achieving concordance on both criteria in six out of seven
patients.
Six weeks after a lanreotide Autogel and octreotide LAR injection only
one had a normal mean GH and IGF-I for age.
Table 2. Deconvolution of 24 h secretory GH profiles in acromegalic patients
on treatment with octreotide LAR and lanreotide Autogel.
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Table 3. Mean GH and IGF-1 concentrations in acromegalic patients
obtained 2, 4, and 6 weeks after injection of octreotide LAR or
lanreotide Autogel.
Discussion
This study is the first report that compares lanreotide Autogel, a new
slow release formulation, with octreotide LAR. Both drugs are long-
acting octapeptide depot somatostatin analogues used for the treatment
of acromegaly (14,18). Both analogues showed similarly suppressed
GH levels during a detailed 24 h study. Moreover, during the regular
injection interval (2 and 4 weeks) and also 6 weeks after the injection,
both drugs equally suppressed mean serum GH and IGF-I concentrations.
The results from this study on lanreotide Autogel differ from previous
studies, comparing lanreotide SR with octreotide LAR. Octreotide LAR,
using one monthly injections generally seems to show a higher efficacy
in suppressing serum GH and IGF-I levels than lanreotide SR, injected
i.m. every 7-21 days (10-13). Lanreotide SR, however, is a different
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preparation than lanreotide Autogel. Lanreotide SR consists of lanreotide
incorporated into micro particles (like octreotide LAR) and is injected
intramuscularly. In contrast, lanreotide Autogel consists of lanreotide-
acetate dissolved in water, and is injected deep-subcutaneously.
Pharmacokinetic studies of lanreotide Autogel in healthy subjects have
shown a release pattern with an almost log-linear decrease of lanreotide
serum levels after a single subcutaneous injection, with a terminal half-
life of approximately 4 weeks (unpublished data from Ipsen- Beaufour).
There is no evidence of accumulation of lanreotide after multiple doses
at any dose neither in healthy subjects nor in patients. Steady state serum
lanreotide levels are reached after 4 doses in most patients (unpublished
data from Ipsen- Beaufour). To date, therapeutic lanreotide levels (>
1000 ng/L) in patients under chronic treatment were documented only
30 days after an injection. On the contrary, octreotide levels following a
single octreotide LAR injection show a totally different release pattern:
immediately after injection there is a small peak followed by an increase
in octreotide levels after 7 days reaching a maximum at 28 days, while
therapeutic octreotide levels (>600 ng/L) are maintained up to 42 days
(19). These differences in pharmacokinetics between the two depot
somatostatin analogues apparently do not result in different efficacy to
suppress GH secretion.
In order to obtain the best possible assessment of the GH suppressive
effect of both analogues we used detailed 24 hr data analyzed with
deconvolution analysis. Both depot preparations are registered for
clinical use with an injection interval of 4 weeks, implicating that  a
safe suppression  of GH and IGF-I is guaranteed up to 28 days after an
injection in octreotide or lanreotide sensitive patients. Hence, we
considered this time point to be the optimal time point for evaluation of
GH secretory profiles in patients on chronic octreotide LAR or lanreotide
Autogel treatment. The 24 h GH deconvolution analyses illustrate that
both long-acting somatostatin analogues, octreotide LAR and lanreotide
Autogel induced comparable suppression of GH secretion. Our in vivo
data are thus in accordance with the in vitro data showing equal binding
affinity for the SSTR 2 and 5 (8).
Recently we showed that patients who had well-controlled GH and IGF-
Octreotide and lanreotide are equally effective in controling GH secretion
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Figure 2. Individual 24 h GH
concentration of each patient measured
28 days after the last injection with
lanreotide Autogel (straight line) or
octreotide LAR (dotted line).
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I levels with monthly octreotide LAR injections, remained well-
controlled in the long-term when the  injection interval was extended to
six weeks (20). Octreotide LAR and lanreotide Autogel showed similar
GH and IGF-I suppression at  2, 4 and 6 weeks. Although the
measurements after four weeks showed a small increase in mean GH
and IGF-1 concentrations in lanreotide treated patients, this was not
statistically significant. Furthermore, mean simulated  GH profiles
calculated from 8 comparable time points during the 24h sampling
studies and the IGF-I concentrations were statistically similar to the
data obtained at 4 weeks of the withdrawal experiment. Therefore, it
might be worthwhile to explore the extension of the injection interval
for chronic treatment with lanreotide Autogel.
With regard to this observation, one should be cautious to interpret
immediate surgical results in patients pre-treated with lanreotide Autogel.
Similar to preoperative octreotide LAR treatment, we suggest postponing
the postoperative biochemical evaluation to 3 months after the last
injection of lanreotide Autogel (19).
Three patients well controlled on octreotide LAR 20 mg, were
individually titrated to the maximum dose of lanreotide Autogel. One
patient using octreotide LAR 20 mg was subsequently well- controlled
with the lowest dose of lanreotide Autogel, e.g. 60 mg/4 weeks. Thus
on an individual basis, different pharmacokinetics, for instance
bioavailability, could lead to discrepancies in effective dosing.
In conclusion, lanreotide Autogel and octreotide LAR were equally
effective in controlling GH secretion in active acromegaly as measured
by suppression of total 24 h GH secretion and by mean GH levels and
IGF-I concentrations. Further analysis should be focused on efficacy in
the long-term.
Octreotide and lanreotide are equally effective in controling GH secretion
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Abstract
Introduction: This study was designed to evaluate potential reversibility
of left ventricular (LV) dysfunction in patients with acromegaly following
long-term control of disease. It is unknown, whether the cardiac changes
induced by acromegaly can be completely reversed by long-term strict
control of growth hormone (GH) excess by octreotide.
Patients and Methods: We compared LV systolic and diastolic function
in inactive patients with acromegaly (n=22) between patients with long-
term control by octreotide (n=14) and patients with long-term cure by
surgery/radiotherapy (n=8). We also assessed these parameters in patients
with active acromegaly (n=17).
Results: In patients with active acromegaly, systolic function at rest
was decreased by 18 % (p<0.01), LV mass index (LVMI) increased by
40 % (p<0.04) and isovolumetric relaxation time (IVRT) increased by
19 % (p<0.01), compared to patients with inactive acromegaly. These
parameters were not different between well-controlled and cured
patients. Using tissue Doppler imaging, the ratio between early- and
late diastolic velocity (E/A ratio) was decreased in active, compared
to inactive acromegaly (0.75 – 0.07 vs. 1.24 – 0.15, p < 0.01). This E/
A ratio was considerably higher in cured, compared to octreotide treated
patients (1.75 – 0.41 vs. 1.05 – 0.1, p < 0.01).
Conclusion: Diastolic function is persistently, and significantly more
impaired in acromegalic patients with long-term control by octreotide
than in surgically cured patients, which points to biological effects of
subtle abnormalities in GH secretion. Criteria for strict biochemical
control of acromegaly, should thus be reconsidered.
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Introduction
Prolonged Growth Hormone (GH) excess can induce myocardial
changes (1-4). These changes include left ventricular hypertrophy,
diastolic dysfunction, systolic dysfunction during exercise, arrhythmias,
and heart failure (5). Recently, regurgitant valve disease has also been
documented in acromegalic patients (6;7). The incidence and severity
of these cardiac changes are related to disease activity and disease
duration. Left ventricular hypertrophy (LVH) appears to be an early
consequence of GH excess (8-11), whereas arrhythmias and valvular
disease are associated with longstanding disease (6;12).
Adequate treatment of GH excess can arrest, and even reverse,
several of these cardiac changes. A total of 19 studies evaluated the
effect of long-term suppression, i.e. 6 months or more, of GH excess on
cardiac function, summarized in Table 1. From these studies, it is evident,
that LV mass decreases, associated with improved systolic and diastolic
function in patients, in whom GH excess is well-controlled. Nonetheless,
it is not entirely clear to which extent long-term successful biochemical
control of GH excess can reverse cardiac function. For instance, although
octreotide treatment improved LV ejection fraction (LVEF), measured
after one year of treatment, LVEF did not normalize completely (8).
Only one study compared cardiac function 5 years after normalization
of GH/IGF-I excess and compared patients with controlled disease and
patients with cured disease. There were no differences in cardiac
function, assessed by radionuclide ventriculography, between patients
wellcontrolled by octreotide and those cured by surgery (13). However,
all non-invasive techniques have major pitfalls insofar as they cannot
measure directly LV pressures.
Recent data question, whether the currently accepted definition
of biochemical control of GH excess, i.e. GH levels < 2.5mg/L and
normal age- and sex-related IGF-1 levels, can be equated with
normalization of all aspects of GH secretion in all circumstances. First,
we showed (15), that long-term treatment of patients with active
acromegaly with somatostatin analogues does not normalize 24-hour
GH secretion, even though all these patients fulfilled the abovementioned
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criteria for strict biochemical control. In contrast, 24-hour GH secretion
in acromegalic patients cured by transsphenoidal surgery was not
different from the values in matched controls. Second, discordant results
between IGF-1 and GH concentrations have been reported in a significant
proportion of newly diagnosed acromegalic patients (16,17). Because
somatostatin analogues do not completely normalize GH secretion, it is
possible that treatment with these analogues aiming at strict biochemical
control of GH excess may not normalize cardiac abnormalities to the
extent of the effects of curation by transsphenoidal surgery.
Therefore, we investigated whether there were differences in
cardiac parameters between patients with long-term control of GH
excess by treatment with octreotide and patients cured by surgery, using
a group of patients with active acromegaly as a reference group. We
used echocardiography including tissue Doppler imaging (TDI), which
allows for a detailed and quantitative assessment of cardiac parameters
including diastolic and systolic function (14).
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Materials and methods
Patients
We studied 39 consecutive patients with acromegaly (19 men)
referred from the outpatient clinic (Table 2). The mean age of the patients
was 56 years (range 20-83 yrs). The diagnosis of acromegaly was based
on the characteristic clinical features and confirmed by insufficient
suppression of GH during a glucose tolerance test (GH nadir below 0.5
µg/L), and the presence of a pituitary adenoma on radiological imaging.
We classified patients according to the presence or absence of
GH excess as having active or inactive acromegaly, resp. The patients
with inactive acromegaly consisted of two groups: 1) well-controlled
patients (n=14): mean fasting GH concentration (measured for 3 hours
with an interval of 30 minutes) < 2.5mg/L, and normal age- and gender-
adjusted IGF-1 concentrations during treatment with depot octreotide
acetate, and 2) patients cured after surgery (n=8): no treatment with
depot octreotide acetate, GH nadir after a 75 gram oral glucose loading
< 0.5mg/L, and normal age- and gender- adjusted IGF-1 concentrations.
Pre-therapy disease severity was not different between the two groups.
The patients with active acromegaly consisted of two other groups: 3)
untreated patients (n=8): no treatment to reduce GH-excess was yet
instituted, and 4) uncontrolled patients (n=9): mean fasting GH
concentrations (measured every 30 min for 3 hours) > 2.5mg/L, and/or
elevated age- and sex adjusted IGF-1 concentrations despite treatment
with maximal dosages of depot octreotide acetate (30 mg i.m. every 3
weeks). Cardiac parameters (see below) were analyzed in groups of
cured and controlled acromegaly, using untreated and uncontrolled
patients as a reference/control groups. None of the patients had
hemodynamic instability, previous myocardial infarction, thyrotoxicosis,
rheumatic fever, endocarditis, anorexigen use, or connective tissue
disease. If hypertension was present (blood pressure > 140/95 mmHg),
medication was prescribed to reduce blood pressure to values < 140/90
mmHg. All subjects had a normal blood pressure for at least 1 year
prior to the study. Glucose tolerance was assessed according to the 1997
ADA criteria: normal: fasting plasma glucose below 6.1 mmol/L,
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impaired fasting glucose (IFG): between 6.1-7.0 mmol/L, and diabetes
mellitus: fasting plasma glucose equal to or greater than 7.0 mmol/L.
None of the female patients was pregnant during 9 months following
echocardiography. The duration of disease was defined by the onset of
clinical symptoms related to GH excess (carpal tunnel syndrome, sleep
apnoea, and arthralgias), and by careful comparison of old photographs.
The end of disease duration was defined as the time of successful (=
cure or well-controlled) treatment. The duration of well-controlled
disease or cure was defined as the time of successful medical treatment
and/or transsphenoidal surgery with/without adjuvant radiotherapy, until
the time of echocardiography.
The local institutional ethics committee approved the study, and
written informed consent was obtained from all subjects.
Echocardiography, Data Acquisition
Echocardiography was performed with the patients in the left lateral
decubitus position using a commercially available system (Vingmed
system FiVe/Vivid-7, General Electric  Vingmed, Milwaukee, WI,
USA). Standard parasternal (long- and short-axis) and apical views (2-
, 4-, and 5-chamber) were obtained. Standard continuous-wave and
pulsed-wave Doppler examinations were performed. M-mode images
were obtained from the parasternal long-axis views for quantitative
assessment of left ventricular (LV) dimensions, fractional shortening
(FS) and left ventricular ejection fraction (LVEF) (10;29). LV mass was
calculated by the cube formula, and using the correction formula
proposed by Devereux, et al.(18;19): 0.8 x {1.04 (LVEDD diameter
+PWD + IVSD)3 + LVEDD3}+ 0.6. LVM indexation (LVMI) was
corrected for body surface area (BSA). LV hypertrophy was defined as
a LVMI above 135 g/m2 for men and 110 g/m2 for women. Systolic
function was evaluated by measurements of FS and LVEF. The following
parameters of diastolic function were measured: diastolic transmitral
peak velocities (E and A wave), the E/A ratio, the isovolumetric
relaxation time (IVRT), and the E-deceleration time. Quantitative
diastolic data were derived from tissue Doppler imaging (TDI) analysis.
For TDI analysis, the digital cineloops were analyzed using commercial
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software (Echopac 6.1, General Electric  Vingmed, Milwaukee, WI,
USA). The sample volume (4 mm3) was placed in the LV basal portion
of the septum (using the 4-chamber images). The following parameters
(mean values calculated from 3 consecutive beats) were derived: early
diastolic velocity (E) and late diastolic velocity (A), and the E/A ratio.
All echocardiographic examinations and analyses were performed by a
single observer, blinded for treatment modalities.
Hormone Assays
GH concentrations were quantitated in duplicate using a sensitive time-
resolved immunofluorescent assay (Wallac, Turku, Finland), specific
for 22 kDA GH protein, and calibrated against WHO IRP 80/505. The
detection limit was 0.012 ìg/L. Intra-assay coefficients of variation were
1.6-8.4% in the GH-range 0.012-18 ìg/L. The total serum IGF-1
concentration was determined by radioimmunoassay (RIA) after
extraction and purification on ODS-silica columns (Incstar corp.,
Stillwater, MN, USA). The intra- and inter-assay coefficient of variation
was less than 11%. The detection limit was 1.5 nmol/l). Age related
normal data were determined in the same laboratory. IGF-1 was also
expressed as a standard deviation score form age-related normal levels.
Statistical Analysis
Univariate analysis of variance was performed to compare groups, and
the Bonferroni multiple comparison as a post hoc test. Linear-by-linear
association was performed to investigate a trend for having untreated,
uncontrolled, well-controlled or cured disease with E/A ratio <1. Data
are expressed as mean – SEM. SPSS software version 11.0 (Inc, Chicago,
USA) was used. Differences were considered statistically significant at
the P<0.05 level.
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Results
Clinical Characteristics
The clinical characteristics are provided in Table 2. GH and IGF-1
concentrations were much higher in patients with active acromegaly,
compared with the values obtained in patients with inactive acromegaly,
reflecting the different inclusion criteria for the different groups.
However, there were no differences in GH/IGF-1 levels between
untreated and uncontrolled patients nor between well-controlled and
cured patients. The duration of controlled GH/IGF-1 levels was not
different between well-controlled patients and cured patients (mean 5.8
years, range 1-14 years, vs. mean 7.9 years, range 2-16 years, resp., P=
NS).
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Table 2. Baseline characteristics
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LV Dimensions and Systolic Function at Rest(Table 3)
LV dimensions were not different between patients with active and
inactive acromegaly. However, LVMI was above the normal range and
40 % higher in patients with active acromegaly, compared with patients
with inactive acromegaly (140 – 17.9 vs. 99.8 – 8.8 g/m2, resp, P<0.04).
LVMI was within in the normal range and not different between well-
controlled and cured patients.
Systolic function at rest, reflected in FS and LVEF, was decreased by
18-19 % in patients with active acromegaly, compared with patients
with inactive acromegaly. FS was 30.3 – 1.8 vs. 37.0 – 1.2 %, resp (P<
0.01) and LVEF was 58.8 – 2.3 vs. 72.6 – 1.8 %, resp. (P<0.01). However,
FS and LVEF were not different between well-controlled and cured
patients.
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Table 3.  LV dimensions and systolic function at rest
62
Diastolic Function (Table 4 and Figure 1)
There were no statistically significant differences in diastolic transmural
peak velocities (E and A waves) between patients with active and with
inactive acromegaly. The isovolumetric relaxation time (IVRT) was
increased by 19% in patients with active acromegaly compared with
patients with inactive acromegaly (109.7 – 4.0 vs. 88.7 – 2.5 ms, P<0.01).
However, there were no significant differences between untreated and
uncontrolled patients, nor between well-controlled and cured patients.
Diastolic function, assessed by TDI (Figure 1), showed that the early
diastolic velocity (E) was significantly higher in cured patients as
compared to the other patient groups (Table 4 and Figure 1). A significant
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Table 4. Diastolic function as assessed by echocardiography and
tissue Doppler imaging.
difference in E was also noted between uncontrolled and well-controlled
patients: E was higher in well-controlled patients (P<0.01), but was
still significantly lower than in those who were cured of disease (P<0.04).
The E/A ratio was considerably decreased in patients with active
acromegaly compared with patients with inactive acromegaly (0.75–
0.07 vs 1.24 – 0.15, P<0.01). In cured patients, the E/A ratio was
significantly higher when compared to well-controlled patients
(1.75–0.41 vs 1.05–0.1, resp, P<0.01). Remarkably, the E/A ratio was
<1 in all untreated patients and in 75% of uncontrolled patients. The
E/A ratio was <1 in 50% of the well-controlled patients versus in only
12% of the cured patients (P=0.003).
Discussion
The present study demonstrates that surgically cured acromegalic
patients had significantly improved cardiac function compared to those
in long-term remission by octreotide treatment. During long-term follow-
up, diastolic function was significantly more impaired in the patients
on medication despite optimal treatment with somatostatin analogues,
according to strict criteria of GH/IGF-1 concentrations.
The question arises whether other factors may have affected our
observations, other than these related to disease activity of acromegaly.
First, the duration of GH excess is a determinant of cardiac abnormalities
(6;8). The group characterized as having active disease had a longer
duration of disease than the cured patients, which will have affected
cardiac function. However, there were no significant differences in
disease duration between well-controlled and cured patients. Second,
the degree of GH excess is a determinant of cardiac abnormalities.
However, there were no differences in GH levels obtained during several
hours or IGF-1 levels between well-controlled and cured patients. Third,
there were no differences in duration of strict control between both
groups. Fourth, there were no differences in BMI or age, which may
have affected our conclusions. Fifth, treated hypertension, which may
have induced diastolic dysfunction, was present in 38% (3/8) of the
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cured patients but in none of the well-controlled group. Moreover, all
patients with treated hypertension had a blood pressure <140/90 mmHg
during the year prior to the study. Finally, the prevalence of diabetes
mellitus and impaired glucose tolerance was not different between cured
and well-controlled patients (25 vs 21%, respectively). Therefore, our
observations are not affected by differences in blood pressure or
carbohydrate metabolism. Based on these arguments, we feel that it is
unlikely that our interpretation of the data is confounded by other
parameters than those related to disease activity of acromegaly. However,
we cannot exclude the possibility that the persistent cardiac impairment
could be due to still unknown factors other than GH hypersecretion,
like asymptomatic ischemia.
Treatment of GH excess favourably affects cardiac function and
mass. To our knowledge, a total of 19 studies involving 312 acromegalic
patients, have been published, which have assessed the effect of
treatment on cardiac function (Table 1). Treatment of GH excess
decreases LV mass and improves diastolic function invariably, whereas
systolic function at rest remained unchanged in most of the studies. Our
data are in accordance with these conclusions of the other publications.
Of the 312 patients, 53% (166 patients) achieved treatment goals, defined
by normalization of IGF-1 and fasting GH levels below 2.5 ìg/L or
glucose-suppressed GH levels below 1 ìg/L. The majority of these
patients, 120/166 (72%), were well-controlled by somatostatin analogue
treatment. In these 120 patients, LV mass normalized and cardiac
function improved. This was mainly reflected by an increase in LVEF
during exercise (20-28), a feature which is already observed within a
few months of treatment with somatostatin analogues. Prolonged
suppression of basal or glucose-suppressed GH levels to values below
2.5 or 1 ìg/L, respectively, in combination with normalization of plasma
IGF-I levels for at least 1 year, resulted in significant improvement, but
not complete normalization, of LVEF either at rest or at peak exercise
without significant changes in diastolic filling (23). These data suggest
that prolonged suppression of circulating GH and IGF-I levels normalizes
systolic cardiac performance. Forty-six of the 166 patients (27%) with
inactive acromegaly were biochemically cured by surgery and/or
Chapter 3
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radiotherapy and were not treated with somatostatin analogues. Hradec,
et al. demonstrated a clear beneficial effect of long-term cure on LVMI,
but diastolic function was not assessed in that particular study (29).
This beneficial effect of cure of GH excess on LVMI was confirmed in
other studies, with a concomitant improvement, but not normalization,
in diastolic function (27,28). The biochemical criteria used in the studies
on cardiac function in acromegaly are based on other studies, which
have shown that these criteria are associated with a reversal of the
increased risk for malignancies and mortality, associated with GH excess
(29,30). However, it is unknown whether biochemical control of GH/
IGF-1 excess, according to these criteria, is also sufficient to normalize
other GH-related morbidity, like acromegalic cardiomyopathy.
The findings in the current study, in patients with long-term
(median of 6 years) control of GH excess, demonstrated that two
independent parameters of diastolic function, the E/A ratio and the
IVRT, improved significantly, indicating ameliorated relaxation and
decreased stiffness of the heart muscle (32). However, a significantly
higher E/A ratio was found in patients cured by surgery when compared
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Figure 1
Diastolic function in patients with acromegaly as assessed by Tissue Doppler imaging
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to those well-controlled with long-term octreotide. Furthermore, Sicolo,
et al. (33) showed that in the presence of diastolic impairment, the
incomplete recovery of an adequate preload can affect systolic
parameters during physical effort. Since systolic function was only
measured at rest, it is possible that systolic function could still be
impaired on effort and hence there might be a difference between those
cured and those in remission. Therefore, these data suggest that
acromegalic patients, well controlled according to stringent criteria,
still reveal biological effects of slight GH overproduction. In accordance,
there are indications that treatment of active acromegaly with
somatostatin analogues resulting in normal IGF-1 and GH levels does
not completely normalize GH secretion. Recently, we investigated 24-
hour GH profiles in uncontrolled and well-controlled acromegaly
patients, treated with long acting somatostatin analogs (34). We applied
the same strict biochemical criteria for well-controlled disease (normal
IGF-I levels and a GH profile during 24-hour GH sampling < 2.5mg/L)
in both groups. However, GH actually was sporadically below 0.5 mg/
L, although chronic treatment with somatostatin analogues repressed
amplitude-dependent measures of excessive GH secretion in acromegaly.
Moreover, tumoral endocrine autonomy was inferred by continued
elevations of event frequency, overall pattern disruption (irregularity),
and nonsuppressible basal GH secretion. We postulate that these subtle
abnormalities in GH secretion relate to the persistently impaired diastolic
function despite clinically normal GH and IGF-1 levels.
In conclusion, long-term control of GH/IGF-I excess is associated
with normal LV mass and LV dimensions. Nonetheless, diastolic function
is more impaired in well-controlled patients than in surgically cured
patients, which proves that the current criteria for strict biochemical
control of acromegaly may still be associated with subtle effects of
excessive GH secretion. Although the clinical relevance of this
observation remains to be determined, these patients might benefit from
more agressive control of GH production, than obtained by applying
the current strict criteria of biochemical control of GH excess.
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Abstract
Cardiac involvement is common in acromegaly, but the prevalence of
valvular abnormalities in patients with acromegaly has not been
documented, and was topic of the current study.
In a prospective study design, 40 consecutive patients with acromegaly
and 120 control subjects (matched for age, sex, hypertension, and left
ventricular systolic function) were studied. All patients and controls
were evaluated using conventional 2D and Doppler echocardiography.
Significant valve disease was more prevalent in acromegalics compared
to controls: 22% vs 6.7% (p=0.005). Aortic valve regurgitation (more
than or equal to trace severity) was present in 30% of patients vs 7% in
controls (p<0.001), mitral regurgitation (more than or equal to moderate
severity was absent in controls, but present in 5% of acromegalics
(p=0.014 vs controls). Binary logistic regression analysis showed a
significant impact only for disease duration on valvular disease, with
an odds ratio of 1.19 (CI 1.028  1.376; p=0.019).
Acromegaly is associated with an increased prevalence of regurgitant
valvular heart disease. This is dependent on the duration of exposure to
increased growth hormone concentrations, with a 19% increase in odds
per year. This increased prevalence of occult valvular disease implicates
that these patients require appropriate follow-up care and monitoring,
especially those with inadequate control of GH overproduction.
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Introduction
Acromegaly is associated with increased cardiac morbidity and mortality.
Recognized manifestations of cardiac disease in this population include
chronic heart failure (CHF) due to either global systolic dysfunction
(cardiomyopathy) or to diastolic dysfunction with preserved systolic
function. The pathophysiology of these cardiac complications of
acromegaly is incompletely understood. It has been hypothesized that
abnormal extracellular matrix regulation by overproduction of growth
hormone (GH) or IGF-1 in patients with acromegaly may contribute to
both systolic and diastolic myocardial dysfunction (1). In addition, GH
can increase circulating pro-inflammatory cytokine levels, like IL-1-
beta and TNF-alpha (2). These cytokines, in turn, increase gene
expression of matrix metalloproteinases (MMPs), that are capable of
altering the composition of the extracellular matrix (3).  These
abnormalities in matrix regulation are associated with cardiac chamber
dilation and reduced myocardial tensile strength (4). Abnormalities in
matrix regulation have also been implicated in the pathogenesis of aortic
and mitral valve disease (5-7)  the latter of which is manifest as thickened
and redundant valves which are incompetent and have an appearance
of myxoid degeneration on pathology.
We hypothesized that patients with acromegaly, in whom GH and IGF-
1 are pathologically elevated,  have an increased incidence of clinically
relevant aortic and mitral valve disease.  There are anecdotal reports of
aortic or mitral valve operations performed in patients with acromegaly
that support this concept (8,9). However, the prevalence of valvular
abnormalities in patients with acromegaly has not been documented.
Therefore, we prospectively evaluated the prevalence of valvular
abnormalities in patients with acromegaly and no prior history of cardiac
disease.
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Methods
Patients and controls
In a prospective study design, 40 patients (19 male and 21 female) with
acromegaly were studied. The median age of the patients was 57 years
(range 20-83  yrs). Nine patients were untreated (de novo patients), and
31 patients were treated either by transphenoidal surgery (n=23) or by
primary medical treatment (n=8) (Table 1). The diagnosis of acromegaly
was based on the characteristic clinical features of acromegaly and
confirmed by insufficient suppression of GH concentration during a
glucose tolerance test and the presence of a pituitary adenoma on
radiological imaging. Disease activity was assessed as follows: Patients
were classified as having active disease if they had mean fasting GH
concentration (measured every 30 min for 3 hours) >5 mU/L and elevated
age- and sex adjusted IGF-1 concentrations. Patients were classified as
having inactive disease if mean GH concentration during fasting 3h
profile were < 5 mU/L and  IGF-1 concentrations were normal. A total
of 18 patients were classified as having active disease (nine de novo
patients and nine patients treated with depot octreotide acetate), and 22
patients as having inactive disease (eight cured patients and fourteen
patients on depot octreotide acetate). Patients with hemodynamic
instability, or a prior history of myocardial infarction, thyreotoxicosis,
rheumatic fever, endocarditis, anorexigen use, or other connective tissue
disease were excluded from the study. Also, in female patients of
childbearing age pregnancy was excluded. None of the patients appeared
to be pregnant in the 9 months following echocardiography. The duration
of disease was defined by the onset of clinical symptoms related to GH
excess (carpal tunnel syndrome, sleep apnea, and arthralgias), and by
careful comparison of old photographs. The end of disease duration
was defined as the time of successful treatment.
Acromegalic patients ar rare, whereas controls with similar age/sex/
comorbidities are not, hence we selected a larger control group. The
acromegaly patients were collected first (with history and examinations)
and 120 appropriate controls were selected based on age, sex,
hypertension, left ventricular systolic function, based on a database with
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this info. We controlled for systolic function to eliminate the possibility
of getting a lot of patients with mitral regurgitation on the basis of left
ventricular enlargement (incomplete closure). Patients were excluded
if they were sent for echocardiac evaluation of known valvular disease,
murmur, congestive heart failure, or cardiac transplant evaluation.
Accordingly, most of the control patients were referred for either atypical
chest pain, palpitations, or syncope without murmur. The study was
approved by the local institutional ethics committees, and written
informed consent was obtained from all subjects.
Echocardiography, Data Acquisition
Patients were imaged in the left lateral decubitus position using a
commercially available system (Vingmed system FiVe, General Electric
 Vingmed, Milwaukee, WI, USA). B-mode 2-D images were obtained
with transmission frequencies of xx-3.5 MHz in the parasternal (standard
long- and short-axis) and apical views (2-, 4-, and 5-chamber images).
Color Doppler echocardiography was performed in all views after
optimizing gain and Nyquist limit. Standard continuous-wave and pulse-
wave Doppler examinations were performed. M-mode images were
obtained from the parasternal long-axis views for quantitative assessment
of LV dimensions, fractional shortening and left ventricular ejection
fraction (10). When tricuspid regurgitation was present, pulmonary artery
pressure was estimated using the modified Bernoulli equation. The
severity of valvular regurgitant was  determined by two independent
expert readers blinded to the clinical data on a qualitative scale of trace,
mild, moderate or severe, using previously described methods (11,12).
Significant valvular disease was determined using the FDA case
definition: mild or greater aortic regurgitation or mitral regurgitation
equal or more than moderate severity (13).
Hormone assays
GH concentrations were quantitated in duplicate using a sensitive time-
resolved immunofluorescent assay (Wallac Oy, Turku, Finland), specific
for 22 kDA GH protein. The detection limit was 0.03 mU/l (0.01 ìg/L).
Intra-assay coefficients of variation were 1.6-8.4% in the GH-range 0.1-
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18 ìg/L (0.26-47 mU/L). The total serum IGF-1 concentration was
determined by radioimmunoassay (RIA) after extraction and purification
on ODS-silica columns (Incstar corp., Stillwater, MN, USA). The inter-
assay coefficient of variation was less than 11%. The detection limit
was 1.5 nmol/l). Age related normal data were determined in the same
laboratory. IGF-1 was also expressed as a standard deviation score form
age-related normal levels.
Statistical analysis
Students t-test was used for continuous variables. The Chi-square test
and the Cochrane-Mantell test were used to compare continuous and
categorical data to detect trends. Binary logistic regression stepwise
was performed to explore possible determinants of valvular disease.
SPSS software version 10.0 (Inc, Chicago, USA) was used. Differences
were considered statistically significant at the p<0.05 level.
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Results
Left ventricular systolic function and dimensions in acromegalic patients
were within the normal range (see Table 2). However, ten patients (25%)
had left ventricular hypertrophy, defined by interventricular septum
thickness (IVST) above 12 mm (n=9) and/or a posterior wall thickness
(PWT) (n=6) above 12 mm. Their corrected Left Ventricular Mass index
(LVMi) was above 110 gr/m2 (for women) and 125 gr/m2 (for men).
Five of these ten patients had significant valve disease. Six patients had
slightly increased LV dimensions (left ventricular end diastolic volume
below 59 mm and < 32 mm, corrected for height, five of whom had
normal left ventricular mass. (four of the six patients had significant
valve disease).
Valvular stenosis was neither seen in patients with acromegaly, nor in
controls. Any valve disease was seen in 50% of patients and in 50% of
controls. Significant valve disease (by FDA criteria) was seen in 22%
(9/40) of patients vs 6.7%  (8/120) in controls (p=0.005) (or even only
4% (5/120) in control subjects if only mitral and aortic valve were
analyzed). Three patients were subsequently operated, two for severe
mitral valve regurgitation, and one for severe aortic valve regurgitation.
The three patients, that underwent valve surgery, presented with
following symptoms prior to echocardiography. The first patient was
diagnosed with a systolic and diastolic murmur on preoperative
79
Increased valvular regurgitation in acromegaly


















'DWDSUHVHQWHGDVPHDQ±6'1RUPDOYDOXHVGHULYHGIRUP-$P6RF(FKRFDUGLRJUDSK\UHIQR
/9(''OHIWYHQWULFXODUHQGGLDVWROLFGLDPHWHU/9(6'OHIWYHQWULFXODUHQGV\VWROLFGLDPHWHU,967LQWHUYHQWULFXODUVHSWXP
WKLFNQHVV3:7SRVWHULRUZDOOWKLFNQHVV)6IUDFWLRQDOVKRUWHQLQJ/9()OHIWYHQWULFXODUHMHFWLRQIUDFWLRQ
 $OOSDWLHQWV  1RUPDO
YDOXHV
/9(''PP   
/9(6'PP   
,967PP
,967!PP

Q 
 
367PP   
367!PP Q   
)6   
/9()   
Table 2. Left ventricular measurements in acromegalic patients
screening for a knee operation. The second patient had palpitations
during physical exercise as a presenting symptom. The third patient did
not experience any symptoms, although he had hypertension.
Prevalence of regurgitation (Table 3)
Aortic valve regurgitation was present in 30% (12/40) of patients vs 7%
(8/120) in controls (p<0.001). These differences were significant for all
grades of severity of regurgitation detected. Significant aortic valve
regurgitation (by FDA criteria) was present in 20% (8/40) of patients vs
4% (5/120) in controls (p=0.002).
Mitral valve regurgitation was detectable in 35% (14/40) of the patients
vs 32% (39/120) of control subjects (NS). However, pathological mitral
regurgitation (moderate or severe according to the FDA criteria) was
absent in controls, but present in 5% (2/40) of acromegalics (p=0.014,
vs controls).
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Table 3. Valvular regurgitation in acromegalic patients (n=40)
compared to controls (n=120).
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Tricuspid valve regurgitation was detectable in 28% (11/40) of the
patients vs 50% (60/120) of control subjects. However, pathological
tricuspid regurgitation (moderate or severe according to the FDA criteria)
was absent in all patients and present in only 3% (3/120) of control
subjects. This difference was not significantly different.
Valvular regurgitation of one valve was present in ten patients, valvular
regurgitation of two valves in two patients, and valvular regurgitation
of three valves in two patients.
Prevalence rates of valvular abnormalities were similar between active
and inactive patients.
Determinants of valvular disease
Figure 1 describes the impact of disease duration on valvular disease in
the acromegalic patients. Binary logistic regression analysis showed a
significant impact of disease duration on valvular disease, odds ratio
1.19 (CI 1.028  1.376); i.e. every additional year of disease would
result in a 19% increase in odds per year.
To explore other possible determinants of valvular disease, binary
logistic regression analysis with a stepwise approach was performed.
The following parameters were analyzed: IGF-1 and GH concentrations
at time of diagnosis, age, active- vs inactive disease, (previous) treatment
with octreotide, and the presence of hypertension. No significant
correlations were found for any of the above mentioned parameters.
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Discussion
This study clearly demonstrates that in patients with acromegaly, valvular
abnormalities are more prevalent than in control subjects, who were
individually matched for left ventricular function, age, sex, and the
presence of hypertension. Moreover, we are the first to show that the
prevalence of valvular disease in acromegaly proves to be highly
significantly correlated to the duration of the disease.
In this study, we compared echocardiographic data in patients with
acromegaly with active or inactive disease to a control data base.
Matched data base analysis is necessary due to the relatively high
prevalence of mild valvular abnormalities in the general population,
which tends to increase with age. Studies using 2D color doppler
echocardiography with a semiquantitative methods for estimating the
severity of regurgitation from trace to severe, have demonstrated that
the population-based prevalence of minimal or mild mitral and tricuspid
valve regurgitation was quite high (58-77%), whereas aortic valve
regurgitation was much less prevalent (14,15). Accordingly, the United
States Food and Drug Administration (FDA) has defined pathological
regurgitation of the mitral and tricuspid valve as more than or equal to
moderate severity, and pathological regurgitation of the aortic valve as
more than or equal to mild severity. However, in the normal offspring
in the Framingham Heart Study (14), trace severity for mitral and
tricuspid valve was present in 75% of the subjects and independent on
age, whereas trace aortic regurgitation was only present in about 5% of
subjects and strongly dependent on age (from about 2% at the age of
26-39 years to about 10% at the age of 70-83 years). Therefore, it has
been postulated, that the FDAs criteria for aortic regurgitation may be
too narrow, and the case definition for pathologic regurgitation may
need to be modified or made age specific (15). In our study, we therefore
individually matched each acromegalic patient for age, sex and the
presence of hypertension, to three non acromegalic control subjects.
We observed prevalence rates of any and significant valvular
regurgitation in these 120 control subjects comparable to those reported
in the normal offspring in the Framingham Heart Study. Aortic
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regurgitation (present in 13% of men and 8% of women in the
Framingham Heart Study) was present in 7% of our control subjects, vs
in 30% of our patients with acromegaly. However, the abnormalities
detected were predominantly mitral regurgitation of trace severity. This
is due to the temporal/spatial high resolution of the echo equipment
available (GE vivid 7, Vingmed system FiVe).
The pathogenesis of myxomatous heart valve degeneration remains
uncertain. Rabkin and co-workers (6), proposed a model in which
activation of interstitial cardiac valve cells leads to the release of
proteolytic enzymes, phenotypic modulation, and proliferation.
Subsequently, degradation of collagen, elastin fragmentation, and
glycosaminoglycans accumulation  produces extracellular matrix
remodeling, and characteristic leaflet myxomatous thickening and
redundancy. However, the primary stimulus for activation of these resting
fibroblast-like interstitial cells remains to be elucidated, but mechanical
stress and genetic abnormalities are proposed to play a key role. In our
three patients who underwent valve replacement surgery, similar
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Figure 1: The impact of disease duration on the prevalence of significant
valvular disease
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pathological changes of myxomatous degeneration were observed
(Figure 2). It is likely that direct or indirect effects of overproduction of
GH are the causes for the observed valvular incompetence, for the
following reasons. First, GH increases gene expression of the matrix
metalloproteinases (MMPs)(16), resulting in abnormal matrix regulation.
Second, recent data indicate that pro-inflammatory cytokine levels are
increased in acromegalic patients with active disease (17). These
cytokines, in turn, can also increase gene expression of MMPs, resulting
in abnormal matrix regulation. Finally, the prevalence of valvular
regurgitation observed in our acromegalic patients proved to be highly
significantly correlated to the duration of the disease. Whereas
pathological valvular regurgitation was absent in patients with an
estimated disease duration of less than 6 years, the prevalence of aortic
valve regurgitation (more than or equal to mild severity), increased from
12.5% for patients with a disease duration of  6 to 10 years, to 40% in
patients with disease duration of more than 16 years. Similarly,
prevalence of mitral valve regurgitation (more than or equal to moderate
severity) was absent in controls, but present in 20% of acromegalic
patients with disease duration of more than 16 years. Whether the
patients had active disease or not at the time of evaluation did not
influence these prevalence rates. From a pathophysiological point of
view this is very interesting, since the valvular damage is apparently
irreversible (in contrast to the already published regression of LVH in
succesfully treated patients). This is also in accordance with the recently
published study by Colao, et al. who reports an unexpectedly high
prevalence of valve abnormalities in patients succesfully cured of
acromegaly (19). Hence, chronic exposure to increased GH or IGF-1
production predisposes for myxomatous degeneration, with a calculated
increase in odds in our study of 19% for the development of valvular
disease for every additional year of exposure to tonically elevated growth
hormone concentrations. Because the onset of GH overproduction is
gradual, there is in general a long patient delay before the diagnosis of
acromegaly is made. Therefore, it can be argued that an acurate
assessment of disease duration is cumbersome. Before the onset of
clinical symptoms, careful comparison of old photographs reveal (often
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subtle, but clear) changes of the face. This retrospective evaluation of
the combination of the onset of clinical symptoms and comparison of
old photographs proved to be reproducible for estimating disease
duration and to find significant associations of this estimated disease
duration with mortality (20), as well as with left ventricular hypertrophy
and cardiac performance (21). However, this way of assessing disease
duration will still lead to inaccuracies. Therefore, we decided to present
the impact of disease duration of acromegaly on valvular disease also
by stepwise increasing disease duration by very large intervals of 5
years. Highly significant increases in the prevalence of valvular disease
were found between every five year interval and the preceding five
years (figure 1). Eventhough there remain uncertanties with respect to
the exact start of acromegaly, this analysis strongly support our notion
that the prevalence of valvular heart disease is dependent on disease
duration.
Figure 2: Mitral valve showing degenerative changes such as
mucoid alteration of the preexistent collagenous
tissue as indicated by the blewish staining (Alcian blue
staining, magnification x 100)
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It is interesting to note that all patients in whom valvular abnormalities
were detected, had normal LV function and that 85% (17/20) of these
patients also had normal dimensions.  This suggests that valvular disease
duration was brief for most patients. The discrepancy between the
relative lack of cardiomyopathic responses in most patients in our study
compared to the recently published study of Colao et al.(19) is striking,
even though we found similar rates of regurgitant valve disease.
However, considering the fact that 57% of our patients had been
adequately controlled for a long time by octreotide therapy, and that
they had similar prevalence rates of regurgitant valve disease as those
without octreotide treatment, the following notion emerges. Octreotide
is known to reverse the development of LVH (22). However, apparently,
this was not reflected in a lower rate of regurgitant valve disease. In line
with this notion we found fibrinoid changes in the valves that were
removed. These changes are in other diseases associated with irreversible
valve disease. Based on the comparison of the data of Colao, et al. (19)
and our study, we hypothesize that regurgitant valvular disease in
acromegaly may be less amnedable to therapeutic intervention aimed
at reducing excessive GH secretion than myocardial complications of
acromegaly.
In conclusion, we are the first to report that acromegaly is associated
with an increased prevalence of regurgitant valvular heart disease, which
is dependent of the duration of exposure to increased growth hormone
concentrations, and which is not associated with impaired left ventricular
function nor hypertension. This increased likelihood of valve disease
may impact the cardiac surveillance of patients with acromegaly and
could provide us more insight on the basic pathophysiological
interactions of growth hormone with connective tissues. The increased
prevalence of occult valve disease implicates that these patients require
appropriate follow-up care and monitoring, especially those with
inadequate control of GH overproduction. Moreover, antibiotic
prophylaxis for any non-sterile procedures may be required.
Acknowlegdments: we acknowlegde Dr. Mary Lee Vance and Todd Belcik for there
help in patient recruitment and data collection.
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Abstract
To assess whether DHEA substitution, superimposed on growth hormone
(GH) substitution, improves quality of life of patients with secondary
adrenal failure, we studied the effects of DHEA (50 mg/day, 16 weeks)
versus placebo (16 weeks) in GH and ACTH deficient postmenopausal
women (n=16, age 61 – 2 yrs) and men (n=15, age 52 – 3 yrs), in a
double-blind, placebo controlled, cross-over study. All patients were
on stable hormone replacement therapy, including a fixed dose of human
recombinant GH during the study. The female patients did not receive
estrogen substitution. The men received testosterone substitution.
At baseline, multiple parameters of quality of life were impaired
compared to age- and sex-matched controls, especially in female patients.
These parameters were not improved by DHEA treatment. DHEA
improved only slightly the depression score (women) and health
perception (women and men), although these parameters were not
abnormal at baseline. DHEA increased serum IGF-I concentrations in
female patients (by ~ 18 %, p< 0.001), but not in male patients. In neither
group, DHEA affected IGFBP-3 levels.
We conclude, that DHEA, superimposed on GH substitution, does not
improve quality of life substantially in patients with secondary adrenal
insufficiency, irrespective of gender. In addition, DHEA increases IGF-
I levels in estrogen depleted females, but not in testosterone treated
males, with secondary adrenal insufficiency.
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Introduction
Growth hormone (GH) deficiency is associated with impaired quality
of life (1) and substitution with recombinant human GH (rhGH)
improves quality of life (1-7). However, despite this beneficial effect of
GH substitution and other pituitary hormones, these patients may still
have significant impairments in multiple aspects of quality of life (8). It
is likely, therefore, that other factors impair quality of life in these
patients.
Many patients with GHD will also have secondary adrenal insufficiency,
and, therefore, decreased levels of dehydroepiandrostenedione (DHEA)
(9;10). DHEA has long been considered as an inactive precursor of sex
steroids. However, deficiency of dehydroepiandrostenedione (DHEA)
due to adrenal insufficiency is associated with impaired quality of life
and treatment with DHEA in subjects with DHEA deficiency
significantly improves quality of life (11-13)(See Table 1). In addition,
beneficial effects of DHEA substitution are reported on other parameters
like insulin resistance and bone mineral density (14-20). These beneficial
effects are attributed to the conversion of DHEA into androgens and
estrogens. Previously, only one study focussed on the effects of DHEA
in female patients with secondary adrenal failure and showed that quality
of life parameters improved (12). Remarkably, in that study quality of
life parameters were assessed predominantly by the partners of the
patients, rather than by the patients themselves.
Therefore, to assess whether DHEA substitution, superimposed on GH
substitution, improves quality of life in male and female patients with
secondary adrenal failure, we studied the effects of DHEA (50 mg/day,
16 weeks) versus placebo (16 weeks) in GH and ACTH deficient
postmenopausal women (n=16) and GH and ACTH deficient men
(n=15), in a double-blind, placebo controlled, cross-over study. All
patients were on stable hormone replacement therapy, including a fixed
dose of recombinant human GH (rhGH) during the study. As previous
studies had not been controlled for estrogen status (Table 1), we chose
to include only postmenopausal women without estrogen replacement
therapy. Men were all on stable testosterone replacement.
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There are indications that DHEA substitution may increase serum levels
of insulin-like growth factor (IGF-I)(Table 1). Because our study was
well controlled for growth hormone availability and DHEA might affect
IGF-1 independently of GH secretion (21), we also evaluated the effects
of DHEA on IGF-1 levels in our study.
Patients and methods
Patients
Patients with pituitary diseases and both ACTH and GH deficiency were
recruited from the Outpatients Clinic of the Department Endocrinology
and Metabolism from the Leiden University Medical Center.
Recruitment of patients took place between October 2001 and April
2002. The Leiden University Medical Center is a large tertiary referral
centre for pituitary disorders. Inclusion criteria were GH deficiency,
proven by insufficient stimulation of GH secretion (GH < 7 mU/L) during
insulin-induced hypoglycemia (minimal glucose concentration after
insulin administration 2.2 mmol/L) with stable replacement therapy with
rhGH for at least 3 months prior to the start of the study, and ACTH
deficiency, proven by insufficient cortisol secretion (cortisol < 0.55 umol/
L) during insulin-induced hypoglycemia, with stable hydrocortisone
replacement therapy for at least 3 months prior to the start of the study.
In all subjects IGF-I levels during treatment with rhGH were in the
mean range of sex- and age matched values. Deficiencies of other
hormones of the anterior pituitary as well as ADH were allowed, as
long as stable substitution with thyroxin and ADH were realized for at
least 3 months prior to the study. Thyroxin was dosed to obtain plasma
FT4 values in the upper 50 % range of the normal reference values. The
dose of thyroxin was stable for at least 3 months prior to starting the
study. For all male participants, stable testosterone replacement by
transdermal testosterone application (50 mg/day) was required
(Testoderm, Ferring Pharmaceuticals, Hoofddorp, The Netherlands). For
female participants estrogen replacement therapy was not allowed.
Exclusion criteria were liver disease, malignant disease or other severe
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Table 1. Overview of studies on the effects of  DHEA substitution in patients with primary and/or secondary adrenal failure
system disease as well as the use of drugs that could potentially interfere
with the assessment of study parameters such as psychotropic drugs.
Study protocol
The study was a randomised placebo controlled, double blind crossover
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Figure 1 Study Flow-Chart.
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study with two treatment periods of 16 weeks separated by an 8-week
wash-out period. A block randomisation scheme was used (n=2) with
stratification for gender. The randomization schedule was prepared by
the Department of Pharmacy. Patients received in random order 50 mg
of Dehydroepiandrosterone (Vito Fit Corp., Helmond, The Netherlands)
or placebo capsules (containing cellulose). Purity and quantity of DHEA
were verified by HPLC analysis at the Department of Pharmacy of Leiden
University Medical Center. DHEA or placebo capsules were taken orally
each morning. rhGH was injected before bedtime. Compliance for study
medication and regular medication was verified at each visit. The
treatment allocation was de-blinded after all study data were authorized
and introduced in a database, that was closed before deblinding.
The Medical Ethic Committee of The Leiden University Medical Center
approved the study protocol, and all patients gave written informed
consent.
Measurements
All visits took place at the outpatient clinic between 8.00 and 10.00
a.m.
Quality of life questionnaires
Quality of life investigation was performed with 5 validated
questionnaires at baseline and at the end of each treatment period. The
questionnaires are described in detail below. Questionnaires were filled-
out in a quiet room in the morning. The baseline measurements were
compared with an age- and sex-matched control group: for each
participant in the DHEA study, 2 age- and sex-matched controls were
selected from a group of 114 healthy relatives of GH deficient patients
from the Department of Endocrinology and Metabolism of the LUMC
(Table 4). The socioeconomic status (level of education, profession,
marital state, living area) of controls and participants was comparable.
Short Form-36
The Short Form (SF)-36 comprises 36 items, which record general well
being during the previous 30 days (22). The items are formulated as
statements or questions and were scored as numbers. Eight parameters
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are calculated with a range of 0-100: physical problems, bodily pain,
general health, vitality, social functioning, emotional role and mental
health. The first three parameters measure physical health, the last three
parameters measure mental health, whereas the general health and
vitality scales are sensitive to both physical and mental health outcomes.
Higher scores represent better quality of life (23).
Quality of life-Assessment of growth hormone deficiency in Adults
The quality of life assessment of GH deficiency in adults (QOL-
AGHDA) is developed specifically to assess the impact of GHD and
GH replacement in adults (24). The items are formulated as statements
and were scored as numbers. Low scores represent better quality of life
(24).
Multidimensional Fatigue Inventory-20
The Multidimensional Fatigue Inventory-20 (MFI20) records fatigue
using 20 statements (25). Five parameters are calculated of the statements
(general fatigue, physical fatigue, reduced activity, reduced motivation
and mental fatigue), with a maximum score of 20 per parameter: A high
score indicates a higher level of fatigue or impairment (26).
Hospital Anxiety and Depression Scale
The hospital anxiety and depression scale (HADS) consists of 14 items
pertaining to anxiety and depression (27). Each item is scored as a
number with a maximal score for each subscale (anxiety or depression)
of 21. Higher scores indicate more severe anxiety or depression. A score
of ‡ 6 on the depression scale or ‡ 7 on the anxiety scale, is considered
abnormal (28;29).
Eleven Questions on Sexual Function
The Eleven Questions on Sexual Function (ESF) questionnaire is
developed by the National Institute for Social Sexual Research (Rutgers
Nisso Group, Utrecht, The Netherlands), with  the Department of
Sexuology of the LUMC. It measures sexual experience during the
previous 30 days using 11 questions. For all patients, 3 parameters are
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calculated out of 8 questions: Sexual fantasies, libido and general sexual
satisfaction. For patients with partners, 3 additional parameters were
calculated related to physical sexual functioning: problems with erection
or lubrication, problems with orgasm and pain or discomfort during
sexual activities. The questions were scored from 1-7, a higher number
indicating a higher degree of satisfaction.
Endocrine parameters
All blood samples were taken between 08.00 and 10.00 A.M., before
regular medication and study drugs were taken, with the exception of
cortisol replacement therapy.
Study parameters were serum measurements of IGF-I, IGF-BP3, DHEA,
DHEA-S, testosterone, estradiol, estrone, SHBG, serum lipids, HBA1C,
and insulin. These measurements were performed at baseline and at the
end of each study period. All blood samples were stored immediately at
80oC until measurement. Other study parameters were anthropomorphic
measurements (weight, BMI, waist-hip ratio).
Safety parameters
A general health questionnaire was done before the study. Laboratory
safety parameters were serum levels of sodium, potassium, ALAT, ASAT,
ªGT, AF and creatinin. Weight, heart rate and blood-pressure were
recorded at every visit.
Laboratory Assays
All analyses of each subject were analyzed in the same run. Total serum
IGF-I concentration was measured by ILMA after dissociation and
blocking of the IGF-binding proteins with IGF-II (Nichols Advantage,
Nichols Institute Diagnostics, San Clemente, CA, USA). Detection limit
was 0.12 ng/ml (0.9 nmol/L). The intra-assay coefficient of variation
(CV) was 4.4-5.2% and the inter-assay CV was 5.7-7.4%. Plasma IGF-
BP3 concentration was measured by RIA (Nichols Institute Diagnostics,
San Clemente, CA, USA). The inter-assay CV was below 6.8 % at the
concentrations measured in the present study. The limit of detection
was 0.0625 mg/L (2.8 nmol/l). Normal values range form 46 to 122
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nmol/l in subjects aged 30-50 years, and 49-112 nmol/l for subjects
between 50-70 years. GH concentrations were measured with a sensitive
time-resolved fluoro-immunoassay (Wallac, Turku, Finland), specific
for the 22-kDa GH. The standard was recombinant human GH
(Genotropin, KabiVitrium, Uppsala, Sweden), which was calibrated
against the WHO First International Reference Preparation 80/505. To
convert mU/L to µg/L, divide by 2.6. The limit of detection (defined as
the value 2 SD above the mean value of the zero standard) was 0.03
mU/L. The intra-assay CV ranged from 1.6 to 8.4 % in the assay range
between 0.26-47 mU/L, with corresponding inter-assay CV of 2.09.9
%. DHEA was measured by RIA after extraction (DHEA-kit, DPC, Bad-
Nauheim, Germany). The detection limit was 0.012 ug/L (0.04 nmol/
L), the intra-assay CV was 5.2-10.8 %, and the inter-assay CV 5.9-11.7
%. DHEA-sulphate (DHEAS) was measured by ILMA (Immulite DPC,
Los Angeles, Ca USA). The detection limit was 148 ug/L (0.4 ìmol/L),
the intra-assay CV 7.0-9.5 %, the inter-asay variation 8-15 %.
Androstenedione was measured by RIA (SL, Sinsheim, Germany), with
a detection limit 0.02 ng/ml (0.07 nmol/L), an intra-assay CV of 2.7-
6.3 %, and an inter-assay CV of 9.3-11.7 %. Total testosterone was
measured by RIA (DPC, Los Angeles, Ca USA) with a detection limit
of 0.08 ng/ml (0.2 nmol/l), and an intra- and interassay CV of 10-19 %.
Estrone was measured using RIA (DSL, Veghel, The Netherlands), with
a detection limit of 1,1 pg/ml (40 pmol/L), an intra-assay CV of  4.4-
9.4%, and an inter-assay CV of 5-17 %. SHBG was measured with
ILMA (Immulite, DPC, Bad-Nauheim, Germany) with a detection limit
of 0.34 mg/L (4.0 nmol/L), an intra-assay CV of 4.1-7.7 % and an inter-
assay CV of 4-20 %. Estradiol was determined with the Elecsys E170
(Roche Diagnostic Systems, Basle, Switzerland), detection limit 1,36
pg/ml (5 pmol/l), with an intra assay CV of 1.6-2.0 % and an inter-
assay CV of 1.6-2.7 %. HBA1C was measured with the BioRad Variant
method (BioRad Laboratories, Veenendaal, the Netherlands) with a
detection limit of 3,6%, an intra-assay CV of 1% and an inter-assay CV
of 1-2%. Serum insulin was measured by IRMA (BioSource, Etten-
Leur, The Netherlands) with a detection limit of 0.1 mU/L (0.6 pmol/
L), an intra-assay CV of 2.1-4.5% and an inter-assay CV of  3.1-4.3%.
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A Hitachi 747 autoanalyzer (Roche Diagnostics, Mannheim, Germany)
was used to quantify serum concentrations of total-cholesterol and
triglycerides with enzymatic tests (all from Roche Diagnostics). High
density lipoprotein (HDL) cholesterol was measured with a homogenous
enzymatic assay (Hitachi 911, Roche Diagnostics). LDL-cholesterol
concentrations were calculated with the Friedewald formula.
Statistics
The sample size was determined by a formal power analysis based on
the rise in IGF-I in the study of Arlt et al (11). In this study, a pooled
standard deviation of changes in IGF-I of 11% was found. It was
calculated that with 2 groups of 15 patients, a rise in IGF-I of 12%
could be detected with 80% power and alpha of 0.05. When no carry-
over effect would be present, a minimal IGF-I rise of even 8% could be
detected.
Data were analysed on a per protocol base. Treatment effects were
analysed using univariate analysis of variance (ANOVA). The model
associated with the ANOVA had an intercept representing treatment
effects. All data were presented separately for men and women. The
effects of treatment were also measured by adjusting for carry-over and
time effects. The tests for carry-over and time effects followed the
procedures described by Hills and Armitage (30). Carry-over and time
effects were also tested.  If no time or carry over effects were detected,
data from both study periods were combined. Categorical data were
analysed with the Chi-square test. Data are presented as mean – SEM.
SPSS for Windows version 11.0 (SPSS Inc., Chicago, IL) was used for
analysing and a p value of 0.05 was considered to be significant.
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Table 2. Baseline characteristics of 31 patients who were treated with
50 mg/day DHEA during 16 weeks or placebo in a randomised
cross-over design with 8-weeks washout.
Results
Clinical characteristics
Thirty-four patients were recruited, 17 women, and 17 men (Figure 1).
One man was excluded before initiation of treatment, because he
developed allergic reactions of the skin to transdermal testosterone
replacement therapy. Therefore, 16 men and 17 women started the study.
One female patient had progression of a non-endocrine pituitary
adenoma, documented by MRI during the first study period, and decided
to withdraw from the protocol. One male patient died at home during
the second phase of the study probably because of an acute myocardial
infarction, but the exact death cause could not be verified as no autopsy
was performed. Data from these 2 patients were not included in the
analyses of the data (see Figure 1). Thirty-one patients (16 women, 15
men) completed the study. The baseline characteristics of these patients
are given in Table 2. No side effects such as acne or greasiness of the
skin were observed in any patient
All women were postmenopausal, and did not receive estrogen
replacement therapy. All men used transdermal testosterone replacement
therapy. All patients had GH deficiency that had been treated for a mean
period of 5.2 – 0.6 years. The causes of pituitary insufficiency are given
in Table 2.
Quality of life: baseline values compared with values obtained in
controls
Quality of life parameters of patients compared with controls are given
in Table 3.  Multiple parameters appeared to be worse in patients than
in controls despite conventional hormonal replacement therapy. In
general, women had more abnormal quality of life parameters than men.
Women scored significantly worse than age and sex-matched controls
in 7 out of 15 tested parameters, whereas men scored worse in 3 out of
15 tested parameters than age- and sex matched controls. In women,
physical functioning (SF-36), role limitations due to physical and
emotional problems (SF-36) and general and physical fatigue (MFI-20)
were worse than in controls. In men, general health perception was worse
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than in controls (MFI-20). Both in men and women, social functioning
(SF-36) and activity level (MFI-20) were worse than in controls.
Quality of life: Effects of DHEA versus placebo
The effects of DHEA on the outcome of the quality of life questionnaires
in female and male patients are given separately in Table 4. There were
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Table 3. Quality of life parameters in 31 patients with substituted ACTH
and GH deficiencies obtained at baseline and 62 age and sex
matched controls.
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Table 4. Quality of life parameters in 31 patients with substituted ACTH
and GH deficiencies after 16 weeks treatment with 50 mg/day
DHEA or placebo
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no carry-over or time effects for any of the study parameters.
Remarkably, parameters that were abnormal at baseline compared with
controls did not improve significantly upon treatment with DHEA. In
women, a significant improvement in the depression score (HADS) was
observed. In both women and men, change in health (SF-36) improved
significantly. DHEA had no effect on the different dimensions of fatigue,
or on parameters of sexual functioning. Patients with partners showed
no beneficial effect of DHEA on sexual performance nor did the
satisfaction about their sex life change.
IGF-I and IGF-BP3 concentrations: effects of DHEA versus placebo
DHEA treatment significantly increased serum IGF-1 levels by ~18 %
in female patients, compared to placebo treatment (p<0.001, Table 5
and Figure 2). In contrast, in male patients, there was no significant
effect of DHEA, compared to placebo, on IGF-I levels (Table 5, Figure
2). DHEA did not influence IGFBP3 levels in female or in male patients.
Other plasma concentrations: effects of DHEA versus placebo
DHEA treatment increased serum levels of DHEA, DHEAS, estrone
and androstenedione substantially in both men and women (Table 5).
DHEA substitution increased estradiol only in women. Interestingly,
after DHEA treatment, androstenedione and estrone levels of women
reached baseline levels of men.
Other parameters: effects of DHEA versus placebo
BMI, waist and waist-hip ratio were not influenced by DHEA treatment.
Fasting serum lipid levels, glucose and insulin levels were not influenced
by DHEA (data not shown).
Side effects of DHEA
There were no side effects reported during DHEA or placebo treatment.
Some patients experienced an increase in perspiration, but this was not
different between both groups. There were no differences observed
between DHEA versus placebo treatment in systolic or diastolic blood
pressures, pulse rate or in safety laboratory parameters.
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Table 5. Endocrine parameters of 31 patients with substituted ACTH and
GH deficiencies at the end of 16-weeks therapy with 50 mg/day
DHEA or placebo
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Discussion
The present study was performed to study if DHEA substitution,
superimposed on replacement with rhGH, has effects on quality of life
in patients with pituitary diseases, resulting in GH and ACTH
deficiencies. At baseline, we found that multiple quality of life
parameters were worse in patients than in controls. This observation
was more pronounced in women than in men. DHEA treatment showed
subtle improvements in a limited number of quality of life parameters
in men and women.  However, these improvements occurred only in
parameters, that were not different from age- and sex matched controls
at baseline.
At present 4 randomized trials have been published on the effect of
DHEA substitution on quality of life parameters in patients with primary
and/or secondary adrenal insufficiency. These studies are summarized
in Table 1. Three studies documented beneficial effects on parameters
of quality of life (11-13). In contrast, the study of Lovas et al. found no
significant effects by DHEA on these parameters (31). However, that
study was criticized, because of being underpowered (32). They used a
parallel group design, which requires a much larger number of patients,
compared to the crossover design of the other 3 studies. In addition,
Lovas et al. used a low dose of DHEA, compared to the other studies
and compared to our study.
With respect to the effects of DHEA in secondary adrenal failure, our
study can only be compared with the study of Johannsson et al. (13).
Although 3 other studies also contained patients with secondary adrenal
failure, their analyses did not include, or did not permit, separate
evaluation of patients with primary versus secondary adrenal failure
(11;12;31). In contrast with the beneficial effects of DHEA on quality
of life predominantly assessed by the partners of the patients reported
by Johannsson et al., we observed only subtle beneficial effects of DHEA
on quality of life reported by the patients themselves.
In the present study we confirmed the impaired quality of life in female
and male patients with pituitary diseases despite conventional hormonal
substitution therapy. DHEA substitution had only limited effects on these
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parameters. It can be proposed that the study is underpowered to detect
significant changes in quality of life. However, the absolute changes in
quality of life scores that were abnormal at baseline were hardly
influenced by DHEA.  The most severely affected parameter, role
limitations due to physical problems (SF-36), changed only from 66.2
(baseline) to 68.8 (DHEA), whereas the control value was 93.4.
Therefore, our data argue against a major effect of DHEA on quality of
life parameters in such patients.
It is presently unclear by which mechanisms DHEA improves quality
of life. The mechanism of action of DHEA is attributed to the conversion
of DHEA into estrogens and androgens. Although this is also reflected
in the changes in plasma concentrations of the respective hormones in
the present study, these hormonal changes were not accompanied by
apparent major changes in quality of life.
Another mechanism could be that DHEA increases quality of life by
increasing IGF-I levels. Remarkably, in the presence of fixed GH
availability, DHEA increased IGF-I levels in estrogen-depleted females,
but not in testosterone treated males, with secondary adrenal
insufficiency. However, the increase in IGF-I was again not accompanied
by an important improvement in quality of life in women.
The study of Arlt et al. indicated that treatment with 50 mg of DHEA
increased IGF-I slightly only in patients with primary adrenal failure,
but not in patients with secondary adrenal failure. These authors
suggested, that this differential effect of DHEA on IGF-I in primary
versus secondary adrenal failure may be due to a GH mediated effect
(11;33). In the present study we controlled for an effect of GH, by
including only patients with GH deficiency on a fixed dose of rhGH
during the whole study. Therefore, an effect of DHEA cannot be caused
by any changes in GH availability. In accordance, other studies did not
find any effect of DHEA substitution in healthy volunteers on GH
secretion (15;21). These observations point to an effect of DHEA,
independently of GH, on IGF-I production and/or clearance. Remarkably,
this effect of DHEA was only present in estrogen-depleted women. In a
study by Span et al (34), it was demonstrated, that estrogen replacement
blunts the IGF-I response to rhGH in women. This could explain why
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in our study effects of DHEA were found on IGF-I in estrogen deplete
women, whereas this effect was not found in the study of Johannsson et
al (13). We did not find an effect of DHEA on IGF-I in testosterone-
substituted men. It is known that testosterone in healthy subjects and
GHD patients enhances IGF-I levels (35-37), which may preclude an
additional effect of DHEA. Apparently, the effect of DHEA on IGF-I
levels is sex- and/or sex hormone dependent.
The absence of relevant effects of DHEA on quality of life points to a
fundamental problem in the concept of conventional hormonal
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 Figure 2 Serum levels of IGF-I and IGF-BP3 in 31 patients at the
end of 16-weeks therapy with 50 mg/day DHEA or placebo.
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substitution. Hormonal substitution therapy has been extremely
successful in the treatment of the major syndromes of endocrine
insufficiency, with respect to reduction of morbidity and mortality.
However, in general, many patients treated for endocrine insufficiencies
still suffer from more or less vague complaints and a decreased quality
of life. It is likely, that these complaints are, at least in part, caused by
intrinsic imperfections of hormone replacement strategies in mimicking
normal hormone secretion (38). Accordingly, the patients with pituitary
diseases evaluated in the present study, showed decreased quality of
life for several parameters, compared with age- and sex-matched
controls, despite optimal endocrine replacement therapy according to
current standards. The fact that DHEA, superimposed on conventional
endocrine therapy, causes only subtle improvements points to our limited
understanding of the mechanisms by which quality of life in these
patients is affected.
DHEA did not affect sexual satisfaction in our study, in contrast to a
positive effect of DHEA in other studies. In healthy subjects, and in
patients primary and secondary adrenal failure, positive effects of DHEA
are described on sexual function (11;13;15;16;31). However, these
studies were carried out in younger patients. In our study, the women
were postmenopausal, almost half of the patients had no partner, and
the men were substituted with testosterone replacement. We cannot
exclude the possibility that these factors may have obscured a potential
positive effect of DHEA on sexual function.
In conclusion, DHEA substitution, superimposed on replacement with
rhGH, has only subtle aspects of quality of life in patients with pituitary
diseases with GH and ACTH deficiencies. Remarkably, DHEA increases
IGF-I levels only in estrogen depleted females, but not in testosterone
treated males, with secondary adrenal insufficiency.
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Abstract
Growth hormone therapy in patients with idiopathic dilated
cardiomyopathy and ischemic cardiac failure has revealed varying effects
on systolic function, probably related to the response in serum insulin
like growth factor I levels. As diastolic function has not been studied
thoroughly, we studied the effects of 6 months of recombinant human
growth hormone treatment on systolic and diastolic function in patients
with ischemic cardiac failure, using cardiovascular Magnetic Resonance
imaging.
Nineteenpatients with ischemic cardiac failure (left ventricular ejection
fraction < 40 %) were studied in a randomized trial. Ten patients received
during 6 months treatment with growth hormone (2 IU/d), 9 served as
controls. Systolic and diastolic function were assessed at baseline and
after 26 weeks by cardiovascular Magnetic Resonance imaging. No
differences were found in systolic and diastolic function between rh
GH treated patients and controls. No change was observed in left
ventricular mass index, end-diastolic volume, end-systolic-volume and
ejection fraction. The treated patients showed no clinical improvement.
Six months of treatment with growth hormone therapy in ischemic
cardiac failure has no favorable effects on left ventricular mass index,
on systolic and diastolic function.
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Introduction
Chronic heart failure still has a poor prognosis despite advances in
pharmacological therapy.1 Therefore, new strategies are warranted to
improve structural myocardial problems such as tissue growth, repair,
and fibrosis, the hallmarks of left ventricular remodeling.2 In this context,
the use of anabolic agents is worthwhile to explore. Experimental data
revealed favorable effects of growth hormone and insulin-like growth
factor (IGF-I) in vitro and in experimental myocardial infarction in rats.3-
8 However, the experimental treatment with recombinant human growth
hormone (rh GH) in patients with cardiac failure of various origins has
revealed discrepant results. Although some non-randomized studies
revealed favorable effects in idiopathic dilated cardiomyopathy9 and
ischemic cardiac failure,10 these favorable effects could not be confirmed
by randomized controlled studies in idiopathic dilated cardiac failure11,12
or randomized13 and non-randomized studies in ischemic cardiac
failure.14
Although the majority of patients with cardiac failure have diastolic
dysfunction,15 randomized studies on the effects of growth hormone in
cardiac failure have only focused on systolic function.11-13 It is not known,
whether growth hormone therapy has a positive effect on diastolic
function. Therefore, the aim was  to investigate in a randomized study
the effects of 6 months therapy with rh GH on systolic and diastolic
function in patients with ischemic cardiac failure using cardiovascular
Magnetic Resonance (MR) imaging.
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Materials and Methods
Patients
Inclusion criteria were the presence of ischemic cardiac disease proven
by prior myocardial infarction and/or coronary angiography, a left
ventricular ejection fraction less than 40% assessed by gated-SPECT
imaging or echocardiography, a stable clinical condition for at least 3
months, and stable medical therapy with ACE-inhibitors, diuretics,
digoxin, nitrates or b-blocking agents for at least 3 months. Exclusion
criteria were myocardial infarction within 3 months before the study,
the presence of a pacemaker or implantable defibrillator, arrhythmias,
chronic renal and liver disease, diabetes mellitus, pregnancy and
malignant disease. The ethical committee of the Leiden University
Medical Center approved the protocol, and all patients gave written
informed consent.
Protocol
Baseline measurements included a physical examination, a 12-lead ECG,
cardiovascular MR imaging and biochemical tests. After baseline
measurements, 22 patients were randomly allocated to treatment with
recombinant human growth hormone (ZomactonR, Ferring
Pharmaceuticals, Hoofddorp, The Netherlands), or non-treatment.
Except for rh GH treatment, the study protocol was identical for the
two groups. rh GH treatment started with 0.5 IU/day, self-administered
subcutaneously. The dose was increased after two weeks to 1.0 IU/day.
Four weeks after entering the study, the final dose of 2.0 IU/day was
initiated and continued until the end of the study at 26 weeks. Safety
visits were performed at 2, 4, 8 and 16 weeks after initiation. At 26
weeks, cardiovascular MR was performed again. At each visit, weight,
waist-hip ratio, blood pressure and heart rate were recorded, and growth
hormone vials were collected to assess compliance.
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Cardiovascular MR
Cardiovascular MR imaging was performed on a Philips 1.5-T ACS-
NT15 MR system with Power Trak 6000 (Philips Medical Systems
International, Best, The Netherlands) using ECG triggering. A stack of
short-axis images consisting of 2 to 12 slices (depending on heart size),
with a thickness of 8 mm and an intersection gap of 1 mm was acquired
using breath hold multishot echo planar imaging. Images encompassed
the entire left ventricle. The imaging protocol was similar as reported
previously. 16
Phase contrast flow velocity measurements across the mitral valve orifice
were acquired using a gradient echo acquisition sequence with
retrospective gating. Velocity maps were acquired across the mitral
orifice using a flip angle of 20 0 and an echo time of 10-12 ms. The
image section had a thickness of 8 mm, a field of view of 350 mm, and
consisted of 2 measurements of a 128 · 128 acquisition which was
interpolated to a display matrix of 256 · 256 pixels. Depending on the
actual heart rate, between 30 and 45 time frames were evenly distributed
over the cardiac cycle, resulting in a temporal resolution of 35 to 39 ms.
Total acquisition time was about 3 min. The maximum phase shift of
180 0  was set to occur at a velocity of 100 cm/s.
Cardiovascular MR Analysis
The MR images and velocity maps were analyzed on a remote
workstation (Sun Microsystems Computer Corp., Mountain View,
California). The left ventricular short axis acquisitions were used to
assess LV dimensions, wall mass, ejection fraction. The endocardial,
epicardial and papillary muscle borders of the end-diastolic and end-
systolic images from each short-axis slice were manually traced using a
MR analytical software system developed at our  institution.17 Myocardial
borders were detected as previously reported.18 The left-ventricular mass
index (LVMI) and left ventricular ejection fraction (LVEF) were
calculated as described before.16
Volumetric flow across the mitral valve was calculated by manually
tracing the borders of the mitral valve in all time frames of the velocity
map series, using flow analytical software package (MEDIS Medical
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Imaging Systems, Leiden, The Netherlands)19. An experienced observer
who was blinded for the treatment modality performed contour tracings.
Flow curves were automatically analyzed following a manual indication
of the start of early filling, peak early filling, peak atrial contribution to
filling, and the end of filling as described previously. 20
Laboratory tests
At baseline and after completion of the study, fasting blood samples
were taken between 0800-0900 h for growth hormone, IGF-I and IGF
binding protein-3 (IGFBP-3) measurements. Serum growth hormone
was measured with the Delfia human growth hormone assay (Wallac,
Turku, Finland). Serum IGF-I was measured by RIA (INCSTAR CORP.,
Stillwater, MN), intra-assay variability was < 11 %; the detection limit
was 1.5 nmol/liter. Normal values are 9-34 nmol/liter for subjects aged
30-50 yr and 8-26 nmol/liter for 50-70 yr.  IGFBP-3 was measured by
RIA (Nichols Institute Diagnostics, Wychen, The Netherlands) with a
detection limit of 0.03 mg/liter and the intra-assay variability of < 8 %.
IGF-I and growth hormone determinations of all subjects were measured
in one assay. Safety laboratory measurements included serum levels of
urea, creatinine, glucose, aspartate aminotransferase, alanine
aminotransferase, and alkaline phosphatase and hematological profile.
Other measurements were performed using routine laboratory methods.
Statistics
Continuous variables are expressed as the mean – SD. Paired or unpaired
Student t-tests were used, when appropriate. To analyze treatment effects,
the differences in treatment response (post-therapy divided by pre-
therapy values) were compared between the groups. A P value of less
than 0.5 was considered significant. SPSS 10.0 (SPSS, Inc., Chicago,
IL) was used for all statistical calculations.
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Results
Baseline measurements
Three patients left the study prematurely for various reasons, not related
to the study. Data from these patients were not included in any analysis.
The baseline characteristics of the 19 patients who completed the study
are shown in Table 1.
Biometric, biochemical aspects at baseline between the two groups are
shown in Table 2. No differences in blood pressure and heart rate were
found between both groups at the start of the study. Baseline IGF-1
levels were within the normal age-adjusted range in all patients (12-35
nmol/l). The rh GH treatment group showed a significant lower level of
IGF-BP3 at baseline compared with the control group (+2.1 – 0.95 mg/
l resp. +2.93 – 0.45 mg/l; P= 0.02).
Cardiac function data measured by cardiovascular MR at baseline are
summarized in Table 2. End-diastolic volume, end-systolic volume,
stroke volume, LVEF and LVMI were not different between the two
groups. In addition, no significant changes were observed in diastolic
function between the groups.
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Table 1. Baseline Characteristics
rhGH therapy in patients ischemic cardiac failure
Effects of rh GH treatment on biochemical and biometric aspects
 The effects of rh GH therapy on biochemical and biometric aspects are
shown in Table 3. Systolic blood pressure decreased slightly in the
treatment group as compared with the control group (+15.8 %; P =
0.05). Diastolic blood pressure and heart rate did not change after
therapy.
rh GH therapy induced a significant increase in serum IGF-1 levels in
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the treatment group, whereas the control group showed a small decrease
(+23.6 – 51 %  resp.  14.0 – 21.2 %; P = 0.05). Serum IGF-BP3 showed
a significant change in the treated group as compared with the control
group  (+58.2 – 68.7 % resp. +4.6 – 27.8  %; P = 0.04).
Serum cholesterol, HDL and triglycerides were not affected by GH
therapy (data not shown). Safety parameters were unchanged.
Effect of rh GH therapy on systolic and diastolic function
Table 4 describes the results of systolic and diastolic function assessed
by cardiovascular MR after 26 weeks treatment. rh GH therapy had no
effect on systolic function. There was no treatment effect observed in
left ventricular dimensions, ejection fraction and left ventricular mass
index.
The early peak filling rate showed a positive change in the treatment
group (+31.5 – 37.5 % versus 0.2 – 17.9 %; P = 0.03). No change was
observed in atrial peak filling rate, and as a result the E/A ratio increased
slightly after 26 weeks in the treatment group (+43.5 – 59.7 % versus
+5.0 – 22.6 %; P = 0.09). Other diastolic function parameters were not
affected by rh GH therapy.
Table 3. Biometric and biochemical aspects after 26 weeks between control group
and rh GH treatment group
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Table 4. Left ventricular dimensions, systolic and diastolic function after 26 weeks between control group and
treatment group
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Discussion
In the present randomised study, we evaluated the systolic and diastolic
function in patients with ischemic cardiac failure after 26 weeks with
rh GH therapy, using cardiovascular MR. No beneficial effects of rh Gh
therapy were observed on systolic and diastolic function. Left ventricular
mass index also remained unchanged.
Chronic heart failure results in increased mortality, despite the
developments in pharmacological therapy.1 Modern drug treatment is
based on the prevention of the progression of heart failure, with ACE
inhibitors, b-adrenergic blockers, spironolactone, digoxin and diuretics.1,2
In the near future strategies may be designed to improve the structural
myocardial problems like tissue growth, repair and fibrosis  (the
hallmarks of LV remodeling).2  In this framework, the use of anabolic
agents to improve the remodeling and therefore the cardiac function is
a worthwhile option to explore. One of these agents, growth hormone
showed promising results in animal studies. Experimental data with
adult cardiomyocytes in rats revealed that IGF-1 enhanced myofibril
development and, concomitantly, down regulates sms a actin, a protein
that forms stressfiberlike structures.4
Administration of IGF-1 given to normal rats leads to hypertrophy of
the heart.5 In animals with experimental myocardial infarction, GH
therapy leads to an improvement or preservation of cardiac function
and induced an increase in myocardial energy reserves.6,7,8 These
observations have led to the assumption that rh GH therapy may result
in improvement of cardiac function in patients with cardiac failure of
various origins without underlying GH deficiency. Experimental studies
with idiopathic dilated cardiomyopathy have shown contradictory results.
In an open study, Fazio et al. found an increased myocardial mass,
reduced left chamber size and improved hemodynamic parameters in
patients with idiopathic dilated cardiomyopathy after 3 months of human
Growth hormone administration.9 In contrast, two randomized studies
that focused on dilated cardiomyopathy, demonstrated that
administration of rh GH for at least 12 weeks had no effect on cardiac
function.11,12 In addition, Osterziel et al. demonstrated an increase in LV
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mass which was not accompanied by a clinical benefit. 11
Studies in ischemic heart failure revealed similar results. Spallarossa et
al. found in a non- randomized study an increase in exercise duration
and well-being, but no effect on cardiac function.14 Genth-Zotz et al.
observed in a  nonrandomised study an improvement in clinical well
being, and a decrease in end-diastolic and end-systolic indexes.10
Although the treatment group showed a significant change of serum
IGF-1, it was observed only in 4 of 9 (44%) patients (Figure 1). Several
explanations for the absence of an effect of growth hormone may apply,
for instance the advanced stage of cardiac failure 21,22 or the concomitant
use of â-blockers.23 In our opinion, the third and most important
explanation may be the existence of growth hormone resistance in
chronic cardiac failure, like in many other chronic diseases.24 Indeed in
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Figure 1. Changes in serum IGF-I in patients with ischemic cardiac
failure after 26 weeks of treatment with recombinant human
growth hormone (2 IU/d) or non-treatment. The dotted line
at 5.8 nmol/l represents the mean IGF-I change of non-treated
patients + 2 SD; * P <0.05.
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chronic cardiac failure, decreased sensitivity to growth hormone has
been observed.25-27 The moderate increase in serum IGF-I concentration
in only 4 of 9 patients in our study as compared with other studies may
be in line with this assumption.10,12,13
Osterziel et al. observed an effect of growth hormone therapy on cardiac
output in patients with idiopathic dilated cardiomyopathy who showed
an IGF-I response above the median response.28 In addition, they
demonstrated a dose-effect relation between short-term growth hormone
application and left ventricular function in ischemic cardiac failure.29
The IGF-I response to growth hormone was related to the severity of
cardiac failure.28,29 In our study, the patients who responded to rh GH
therapy had a comparable LVEF as observed in non-responders;
moreover, the responders did not improve their systolic or diastolic
function after treatment. The existence of a threshold for growth hormone
therapy, could explain why in this study no effect was found of growth
hormone on cardiac function. Future studies require a distinct increase
in circulating IGF-I by giving each patient an individual dose.
The present study showed, that 26 weeks of 2 IU/day rh GH had no
beneficial effect on systolic and diastolic function. Further studies are
warranted to evaluate the application of growth hormone in earlier stages
of ischemic cardiac disease and regarding individual dose adjustment
depending on the IGF-I response.
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Introduction
The clinical approach to new patients in internal medicine proceeds
according to a standard diagnostic sequence, before therapy can be
instituted. This clinical process starts with a detailed medical history,
followed by physical examination. Additional investigations, like
laboratory and/or radiological tests, are based on the differential
diagnosis made after these first steps. The results of these diagnostic
tests enable to confirm the initial diagnosis or to limit the initial
differential diagnosis. Sometimes additional tests are required. Finally,
based on the principles of evidence-based medicine the patient will
receive appropriate treatment. Unfortunately, this clinical approach is
not always perfect and doctors need to know the imperfections of the
diagnostic and therapeutic approaches. In this thesis some of these
imperfections of the diagnosis, treatment and follow up are discussed,
with a focus on clinical conditions characterized by growth hormone
excess or -deficiency.
Acromegaly
Patients with acromegaly can only be cured by successful trans-
sphenoidal surgery. However, this procedure cures only ~60 % of the
patients with acromegaly. Moreover, during long term follow up of these
initially cured patients, the disease may reoccur, resulting in an overall
long term cure rate of only 40-50 %. Patients with persistent recurrent
acromegalic disease require additional treatment to prevent increased
morbidity and mortality. These additional treatments consist of
somatostatin analogues, a growth hormone receptor antagonist, or
radiotherapy. Several questions have not been resolved in detail. When
is such operation successful? What are the criteria to decide that
abnormal growth hormone secretion is well controlled? Which patients
require adjuvant therapy? What is the relevance of discrepancies between
GH and IGF-I levels? With respect to this last issue, several studies
have demonstrated discrepancies between IGF-I and GH levels after
surgery. For instance, one study showed that 19 % of the patients had
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normal GH levels but high IGF-I, and 8 % of the patients had elevated
GH but normal IGF-I. In the group of paients with normal GH levels
but high IGF-I another study showed that 50 % had a normal glucose-
mediated GH suppression after glucose tolerance test according to the
current criteria.
Mortality studies showed that the control of GH hypersecretion leads to
a mortality risk, that is not different from the normal population. Based
on these studies the biochemical goals of treatment of acromegaly have
been defined: random GH levels should be < 2,5 µg/L, the nadir GH
levels during OGGT nadir should be < 1 µg/L and/or IGF-I levels should
be in the normal range of age- and sex matched controls. The use of the
mortality studies to define the criteria for well-control of GH excess
has definite limitations. During the long term follow up required in
these mortality studies, there is a lot of change in treatment modalities,
e.g. better medication, change to more sensitive assays, loss of data,
which influence the interpretation of the results. Therefore, the outcome
of treatment in mortality studies is a reflection of older treatment
modalities confounded by newer developments. Another problem is that
these mortality studies used different biochemical parameters, e.g.
random or postabsorptive GH measurements, GH levels after OGTT,
and IGF-I levels, which make the comparison between the different
studies not always straightforward. Also most studies used last known
biochemical data what results in selection bias, because the subjects
with the longest follow up will have the lowest biochemical parameters.
Somatostatin therapy is currently an accepted medical treatment used
as adjunctive treatment after initial transsphenoidal treatment. Several
studies have also advocated somatostatin analogues as primary treatment.
In both conditions somatostatin analogues are effective in controlling
GH excess in ~60 % of the patients, according to the criteria derived
from the mortality studies. At present two somatostatin analogues with
slow release modalities are available: octreotide LAR and lanreotide
Autogel. Instead of the parabolic increase of octreotide levels seen during
4 weeks after subcutaneous injection with octreotide LAR, lanreotide
has a more log-linear decrease of its levels during 4 weeks after its
137
Discussion and summary
intramuscular injection. In chapter 2 a comparison was made between
these two long acting depot preparations with respect to their ability to
suppress GH levels in one group of well-controlled acromegalic patients.
Both analogues have almost the similar binding capacities to
somatostatin receptor subtype 2 and to a lesser extent to subtype 5. We
used two different approaches to compare the efficacy of both methods.
First, we measured mean fasting GH levels and IGF-I levels at 2, 4 and
6 weeks after injections of the analogues. Secondly, 24 h GH secretion
profiles were compared at 4 weeks after administration of each analogue.
There were no major differences between the effects of both analogues
on GH levels or IGF-I concentrations. Although the number of subjects
included in the study was limited, the detailed analysis of GH dynamics
support the emerging notion that there are no major differences in
efficacy between both somatostatin analogues, despite the difference in
pharmacokinetics.
Although the patients described in chapter 2 were well controlled during
treatment with somatostatin analogues according to accepted criteria,
the study described in this chapter also showed that patients have
persistently high GH levels during 24 h. This indicates that the definitions
of biochemical control of GH excess derived from mortality studies
should not be equated with normalization of GH secretion. In contrast,
normalization of GH secretion occurs after successful transsphenoidal
surgery. The question arises to what extent the subtle abnormalities in
GH secretion that persist during somatostatin treatment translate into
biological effects.
Adequate control of GH excess, employing the criteria derived from
the mortality studies, normalizes the reversible manifestations of
acromegaly such as sweating, carpal tunnel syndrome, diabetes mellitus,
dyslipidemia, and soft tissue swelling. The problem with such parameters
is, however, that they cannot easily be quantified by clinicometric or
other methods. Therefore, in clinical practice we mostly rely on the
effects of treatment on biochemical parameters (GH and IGF-I).
With respect to the heart, control of GH excess has clear effects, reflected
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in a decrease of the increased left ventricular mass, improvement of
systolic function at exercise and diastolic function. We wondered whether
we could use the heart as a biomarker to compare the effects of different
treatment modalities of GH excess in patients, who were well controlled
for GH excess. Therefore, in chapter 3, we compared cardiac function
between acromegalic patients cured by transsphenoidal surgery,
acromegalic patients well controlled by somatostatin analogues, still
active patients despite somatostatin analogues and de novo acromegalic
patients prior to any treatment. We assessed cardiac parameters, using
tissue Doppler assessment. The study showed that diastolic function
was improved in patients who were no longer exposed to active disease.
However, patients well- controlled by treatment with somatostatin
analogues still had impaired diastolic function, indicating persistent
effects of GH excess. This observation was present during tissue Doppler
imaging, but not during conventional echographic assessment, reflecting
the improved sensitivity of tissue Doppler imaging for detecting subtle
differences in diastolic function. The clinical relevance of this subtle
diastolic impairment is presently unclear. This was one of the first studies
that differentiated patients with biochemical control of GH excess by
dividing this group in well controlled and cured patients. By using a
new technique to assess diastolic function we proved that some
acromegalic patients well controlled according to the current
biochemicalcriteria, derived from the mortality studies, still have slightly
active disease. However, these patients had no other clinical symptoms
and the clinical relevance of our observation for patient care is at present
uncertain. Nonetheless, the observations in chapters 2 and 3 indicate,
that the standard approach of the internist, proceeding from medical
history, physical examination and appropriate diagnostic tests, fails to
detect subtle, but persistent disease both with respect to biochemical
parameters and with respect to the subtle effects on the heart.
During the studies described in the present thesis, we made an intersting
obervation. Although acromegaly was known from 1886, and
cardiovascular disease plays an important role in the increased morbidity
and mortality rate associated with acromegaly, it was astonishing to
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conclude that there was hardly any documentation of the effects of GH
excess on the function of the cardiac valves. We stumbled upon this
question, when several of our patients had documented insufficiencies
of the mitral and/or aortic valves. Despite long term follow up studies
and many studies involving echocardiography there was no notion of a
relation between acromegaly and cardiac valve disease.  In chapter 4
we compared the prevalence of cardiac valve disease in acromegalic
patients and matched controls. Therefore, we performed
echocardiography in 40 patients with cured, well-controlled disease, or
active acromegaly to assess if there was any valvular insufficiency
compared with 120 healthy controls, matched for age, sex,blood pressure,
and left ventricular systolic function. The prevalence of significant
valvular insufficiency was more than threefold increased in the group
of the acromegalic patients (22 % vs. 6.7 % in controls). Pathological
aortic valve regurgitation was present in 20 % of the patients present
compared with 4 % of the controls. Pathological mitral regurgitation
was only present in 5 % vs. 0 % in controls. Interestingly, none of the
patients with valvular insufficiency had symptoms or were previously
known to a cardiologist. Nonetheless, the regurgitation found had clinical
significance, according to the participating cardiologists. A longer
duration of exposition to GH excess was associated with an increased
prevalence of valvular insufficiency. We postulate that the damage that
occurred to the cardiac valves is irreversible, in contrast to some other
manifestations of acromegaly. This is based also on the histological
examination of one of the valves obtained from an acromegalic patient
after cardiac surgery.  In conclusion, there is a high prevalence of valvular
regurgitation in acromegalic patients, which most likely depends on the
duration of GH excess. Apparently, the standard approach of the internist
including medical history and physical examination has failed to detect
this important complication of acromegalic disease in the 120 years
after this disease was initially described. Therefore, patients with active
acromegaly require echocardiographical examination to assess the
valvular damage, because this may not be detected by a standard physical
examination. This may have consequences for their treatment.
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Growth hormone deficieny
Diseases resulting in damage to the somatotrophic cells in the pituitary,
cause GH deficiency. The syndrome of adult GH deficiency results in
subtle changes in physical and biochemical parameters and in aspecific
changes in quality of life. It is currently recommended to treat these
patients with recombinant human GH (rhGH) aimed at IGF-I levels in
the upper range of normal to improve cardiovascular morbidity. Because
the complaints and physical effects of GH deficiency are subtle and
aspecific, there are no good clinicometric or biochemical parameters to
titrate the treatment with rhGH other than IGF-I concentrations. In
addition, there are intrinsic imperfections with respect to physiological
GH replacement. GH is secreted in a pulsatile fashion, which cannot be
mimicked by a once daily injection of rhGH. Moreover, patients with
pituitary insufficiency frequently have additional endocrine
insufficiencies, with additional intrinsic limitations in physiological
replacement. Despite adequate replacement of these endocrine
insufficiencies, the quality of life of patients with pituitary disease may
improve, but remains impaired to a certain extent.
In chapter 5 we evaluated quality of life in patients with long-term
replacement with rhGH. A broad spectrum of quality of life parameters
was investigated and compared to age- and sex-matched controls. In
general, women had a greater impairment in quality of life parameters
then men. In GH deficient female patients the domains physical
functioning, role limitations due to physical and emotional problems,
measured by the SF-36, and general and physical fatigue, measured by
MFI-20, were worse than in controls. Moreover, both male and female
GH deficient patients had problems in social functioning, together with
impaired activation. The general health perception in men was impaired
compared with controls. These results were interesting, because although
most patients had a long-term follow up, we had limited knowledge of
the quality of life of our patients. Apparently, the standard approach of
internists is not suited to assess quality of life in patients, even though
this is one of the main goals of treatment in patients with GH deficiency.
Several years ago positive results of DHEA substitution were reported
in subjects with primarily adrenal insufficiency. DHEA and its sulfate,
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DHEA-S, are strange steroids. Although their concentrations are several
folds higher than that of any other adrenal gland hormone, the function
of these hormones is still not clear. In humans, no receptor has been
found for DHEA or DHEA-S. It is postulated that they serve as precursors
for active steroids intracellularly, for instance in the brain. By restoring
DHEA to physiological levels, the quality of life improved. An interesting
side effect was noticed in women consisting of a rise in IGF-I levels.
Therefore, the question arose whether the improvement of quality of
life and the rise of IGF-I were related to each other.
In chapter 5 the data are presented of a double blind crossover study of
the effects of DHEA versus placebo in GHD patients to address this
question. DHEA restored the adrenal gland hormone concentrations to
normal levels. In general, the patients perceived a positive change in
their health.  Nonetheless, we observed that they were not able to describe
exactly what aspects improved. The only positive change was observed
in women who showed an improvement in the depression score (HADS).
The general approach of internists of taking the medical history is
inadequate for assessing subtle changes in quality of life, such as assessed
by detailed questionnaires. Nonetheless, the use of questionnaires has
limitations. Quality of life is something abstract that is difficult to
determine and each subject may have slightly different interpretations
of his/her quality of life. Another problem is related to the selection of
the controls, which may be subject to bias. On the other hand, reference
data from the literature may not be applicable to the study population.
Therefore, we decided to use each subject as his/her own control.
In women, the small improvement in quality of life was not associated
with the increase of IGF-I levels. Remarkably, IGF-BP3 levels, the major
GH binding protein in the plasma, did not increase, indicating that the
increase in IGF-I levels was not merely the result of increased binding
proteins. Because all patients had a fixed dose of rhGH, increased GH
availability was another unlikely explanation of the increase in IGF-I
levels. We studied only postmenopausal women with hypopituitarism
without hormone replacement therapy, whereas we studied men with
hypopituitarism who were all on testosterone substitution. We speculate
that this difference in hormone substitution between men and women
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and/or gender may have been involved in the discrepant results of DHEA
substitution on IGF-I levels. Nonetheless, from a practical perspective,
at present postmenopausal women do not receive standard estrogen
supplementation, whereas men above the age of 50 years still receive
testosterone supplementation.
In chapter 6 the date are presented of a prospective, randomised,
controlled study on the effects of GH substitution in patients with
ischemic cardiac failure. The basic concept derived from other studies
was that cardiomyocytes have receptors for GH and IGF-I and that GH
treatment may be of benefit in certain patients with impaired cardiac
function. The patients received rhGH in dosages normally given to GH
deficient patients. Unfortunately, there was no effect on cardiac function
after 6 months of treatment. This randomised study proved that GH
substitution in patients with normal endocrine functions is not of benefit
for ischemic cardiac dysfunction. The question arises whether the initial
ideas of performing such studies in this group of patients without any
endocrine dysfunction were solid. In the early nineties observational
studies of rhGH treatment were reported in small groups of patients
with heart failure, which demonstrated a positive change in left
ventricular mass and systolic function. Moreover, there were suggestions
that these patients had a disturbed GH-IGF-I axis reflected in decreased
IGF-I levels. Subsequently, a large study in intensive care patients proved
that GH substitution caused excessive mortality. In this respect, a parallel
with the effects of thyroid hormone substitution in patients with non-
thyroidal illness can be made. In these patients so far no consistent
clinical benefit of thyroid hormone substitution has been demonstrated.
The changes in hormone concentrations in response to non-endocrine
disease reflect the adaptive capacity of the human body. Before
interfering in the human body, one should understand the underlying
pathophysiological mechanisms of the changes observed. It is interesting
that all the studies performed in cardiac failure with GH were based on
one uncontrolled study, and that later this hype was finished by
prospective, randomised studies.
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Concluding remarks
Internists use a standard approach to evaluate signs and symptoms of
patients, supplemented by diagnostic tests, in order to make a diagnosis,
to assess the activity of the disease and to evaluate the effects of
appropriate treatment. Against this background the clinical syndromes
of GH excess and GH deficiency impose several difficulties. With the
exception of advanced cases of acromegaly, the signs and symptoms of
both syndromes can be subtle and aspecific. Consequently, they cannot
easily be quantified by clinicometric methods.
The studies described in the current thesis highlight several limitations
of the standard approaches of internists. The association between
acromegaly and valvular heart disease escaped the attention of the
attending physicians for more than 120 years (chapter 4). In the
assessment of disease activity and of the effects of treatment we have to
rely on biochemical criteria for both GH excess and GH deficiency. For
the treatment goals of acromegaly, the current criteria have been derived
from mortality studies. However, acromegalic patients still have subtle
GH overactivity during treatment with somatostatin analogues despite
being well controlled according to these criteria. We obtained evidence
for biological effects of this subtle GH overactivity at the level of the
heart, i.e. diastolic dysfunction was present in these patients, but not in
patients cured from active acromegaly by surgery (chapter 3). There
appeared to be no difference between two different somatostatin
analogues with respect to biochemical control of active acromegaly
(chapter 2).
The studies in the patients with GH deficiency indicate that our current
clinical approaches are not able to assess the effects of treatment with
respect to the effects on quality of life. Using structured questionnaires,
we were not able to show improved quality of life in GH deficient
patients with secondary adrenal insufficiency by adding DHEA
substitution although patients experienced a subjective change (chapter
5). Finally, our treatment of diseases should be based on solid evidence
of underlying pathophysiological mechanisms. GH substitution in
subjects without endocrine disease but with ischemic cardiomyopathy
did not have major effects (chapter 6). However, in retrospect the
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evidence for the involvement of GH in the pathophyioslogy of heart
disease in patients without GH deficiency or overproduction was only
circumstantial.
145
Discussion and summary
146
Hoofdstuk 8
Discussie en samenvatting
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Inleiding
De klinische benadering van nieuwe patiºnten in de interne geneeskunde
verloopt volgens een standaard stramien, voordat therapie wordt gestart.
Dit begint met een gedetailleerde anamnese en beschrijving van de
medische voorgeschiedenis gevolgd door lichamelijk onderzoek.
Aanvullend onderzoek, zoals laboratorium- en/of radiologische tests,
zijn gebaseerd op de differentiaal diagnose gemaakt na de eerste stap.
De resultaten van deze diagnostische tests bevestigen de initieel al
vermoedde diagnose of limiteren het aantal mogelijkheden van de
differentiaal diagnose. Soms zijn er extra testen nodig. Uiteindelijk zal
de patiºnt de juiste behandeling krijgen, gebaseerd op de principes van
evidence-based medicine. Helaas is deze klinische benadering niet
altijd perfect en de dokter dient dan ook op de hoogte te zijn van de
imperfecties en dus beperkingen van de diagnostische en therapeutische
mogelijkheden. In dit proefschrift zullen sommige van deze imperfecties
bij de diagnose, behandeling en de follow-up worden besproken, met
de nadruk op de klinische gevolgen van groeihormoon overschot en -
tekort.
Acromegalie
Patiºnten met acromegalie kunnen alleen succesvol worden behandeld
door transsphenoidale chirurgie. Echter, hierdoor worden maar 60 %
van de acromegale patiºnten gecureerd. Sterker nog, bij langdurige
follow-up blijkt dat er bij een aantal een recidief optreedt bij deze in
eerste instantie gecureerde patiºnten, hetgeen ertoe leidt dat de overall
cure rate daalt naar maximaal 50 %. Patiºnten met persisterende ziekte,
of een recidief, dienen additionele therapie te ontvangen, zodat het
toegenomen risico op mortaliteit en morbiditeit kan worden voorkomen.
Deze additionele therapie bestaat uit somatostatine analogen,
groeihormoon receptor antagonisten of radiotherapie. Een aantal vragen
zijn echter nog niet beantwoord. Wanneer kan men spreken van een
succesvolle operatie? Wat zijn de criteria om te bepalen of de abnormale
GH secretie goed onder controle is? Welke patiºnt heeft additionele
therapie nodig? Wat is de relevantie van de discrepantie tussen GH en
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IGF-I concentraties? Meerdere studies hebben laten zien dat er een
verschil is tussen IGF-I en GH concentraties na operatie. Bijvoorbeeld,
een studie toonde aan dat 19 % van zulke patiºnten een normale GH
concentratie had maar een hoog IGF-I, en 8 % had verhoogde GH
concentraties maar een normaal IGF-I. Een andere studie toonde aan,
dat 50 % van de patiºnten met een discrepantie tussen GH en IGF-I een
normale glucose-geïnduceerde suppressie hadden na de OGTT volgens
de huidige criteria.
Mortaliteit studies tonen aan, dat de controle van de GH hypersecretie
leidt tot daling van het mortaliteits risico tot een waarde die gelijk is
aan die van de normale populatie. Op deze studies zijn de biochemische
criteria voor de behandeling van acromegalie gebaseerd: een random
GH concentratie beneden  2,5 ug/L, een laagste GH spiegel gedurende
een glucose tolerantietest van minder dan  <1 ug/L en/of normale IGF-
I concentraties voor leeftijd en geslacht. Het gebruik van
mortaliteitsstudies voor de definitie van goed gecontroleerde GH
overschot heeft duidelijk beperkingen. Door de langdurige follow-up
nodig die nodig is in deze studies, treden er veranderingen in de
behandelingstrategieºn,  komen er nieuwere, sensitievere laboratorium
tests, is er verlies van data, hetgeen allemaal invloed heeft op de
interpretatie van de resultaten. Dus, de uitkomst van de mortaliteit studies
is een reflectie van oudere behandelingsstrategieºn, vertroebeld door
nieuwe ontwikkelingen. Een ander probleem is dat mortaliteit studies
gebruik maken van verschillende biochemische parameters, zoals
random metingen van het GH in de periode na de operatie, GH waarden
na OGTT en IGF-I concentraties, wat de vergelijkingen tussen studies
moeilijk maakt. Tenslotte, de meeste studies gebruiken de laatst gemeten
biochemische data wat resulteert in een selectie bias, omdat patiºnten
met de langste follow-up de laagste biochemische parameters hebben.
vergeleken 4 weken na injectie. Er werden geen verschillen in de
effectiviteit van de twee analogen gevonden. Ondanks dat het aantal
patiºnten beperkt was in de studie, steunden de resultaten van de
gedetailleerde analyse van de GH dynamiek de conclusie, dat er geen
verschillen waren in effectiviteit van beide somatostatine analogen,
ondanks de verschillen in farmacokinetiek.
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Ondanks het feit dat de patiºnten beschreven in hoofdstuk 2, well-
controlled waren voor GH overproductie gedurende de behandeling
met beide analogen volgens de huidige criteria, toonde de studie aan
dat de patiºnten gedurende 24 uur verhoogde GH concentraties hadden.
Dit betekent dat de definities van biochemische controle gebaseerd op
mortaliteit studies niet gelijk staat aan normalisatie van de GH secretie.
Dit staat in contrast met de observaties dat na een succesvolle operatie
van acromegalie, de GH concentraties wel normaal zijn. De vraag is
dan ook in hoeverre de iets hogere GH concentraties bij well-controlled
patiºnten met somatosatine behandeling leiden tot biologische effecten.
Adequate controle van de overmatige GH secretie, volgens de criteria
gedestilleerd uit mortaliteit studies, normaliseert de reversibele
symptomen van acromegalie, zoals overmatig transpiratie, weke delen
zwelling, carpaal tunnel syndroom, diabetes mellitus en dyslipidemie.
Het probleem met zulke parameters is, dat ze moeilijk zijn te
kwantificeren door klinische of andere methodes.
Daarom vertrouwen we in de dagelijkse praktijk meer op biochemische
parameters (GH, IGF-I) om het effect van de behandeling van
acromegalie te beoordelen.
Met betrekking tot de effecten van acromegalie op het hart, heeft controle
van de overmatige GH secretie duidelijke effecten, zoals vermindering
van de toegenomen linker ventrikel massa, en verbetering van de
systolische- en diastolische functie. Wij vroegen ons af of het hart kan
worden gebruikt als biochemische marker om het effect van de
verschillende behandelingen van GH overschot te vergelijken. Daarom
hebben we in hoofdstuk 3 de cardiale functie vergeleken tussen
acromegale patiºnten gecureerd door transsfenoidale chirurgie, well
controlled door somatostatine analogen, niet goed gecontroleerde
patiºnten ondanks somatostatine analogen en nieuwe acromegalie
patiºnten die nog niet behandeld waren. Voor het meten van de
verschillende hartfuncties maakten we ook gebruik van tissue Doppler
echocardiografie. De studie toonde aan dat in patiºnten de diastolische
dysfunctie was verbeterd in patiºnten die geen actieve ziekte meer
hadden. Echter, bij de patiºnten die well-controlled waren met
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analogen was er nog steeds sprake van enige diastolische Therapie met
somatostatine analoga is nu een geaccepteerde medische behandeling,
die wordt gebruikt als adjuvante therapie na een initiele transsphenoidale
behandeling. Meerdere studies tonen aan, dat somatostatine analogen
ook kunnen worden toegepast als primaire therapie voor acromegalie.
Bij beide mogelijkheden zijn somatostatine analogen effectief in de
suppressie van de overmatige GH productie bij ~60 % van de patiºnten,
volgens de huidige criteria gebaseerd op mortaliteit studies. Er zijn
momenteel twee slow-release somatostatine analogen op de markt:
octreotide LAR en lanreotide Autogel. In plaats van de parabole stijging
van octreotide concentraties gedurende 4 weken na een subcutane
injectie, laat lanreotide Autogel een meer log-lineaire daling zien van
lanreotide concentraties volgend op de piek na een diep-subcutane
injectie. In hoofdstuk 2 is een vergelijkende studie beschreven tussen
deze twee depotpreparaten, die beide in staat zijn om GH te
onderdrukken, in een groep van acromegale patiºnten, die goed
gecontroleerd waren voor hun GH overproductie. Beide analogen hebben
nagenoeg dezelfde bindingscapaciteiten voor de somatostatine receptor
2, en in minder mate voor receptor 5.  We hebben gebruik gemaakt van
twee verschillende methoden om de effectiviteit van de beide te
vergelijken. Bij de eerste methode hebben we de gemiddelde nuchtere
GH concentraties gemeten 2, 4 en 6 weken na een injectie van een van
de analogen. Bij de tweede methode hebben we de 24 uurs GH
profielendysfunctie, wat betekent dat er nog steeds sprake is van
persisterende effecten van GH overmaat. De waarneming werd alleen
gevonden bij de metingen met tissue doppler, en niet tijdens de normale
conventionele meting, wat aangeeft dat Tissue doppler sensitiever is in
de meting van subtiele verschillen van diastolische functie. De klinische
relevantie van de diastolische dysfunctie is nog niet helemaal duidelijk.
Deze studie was een van de eerste die differentieerde tussen de
biochemische controle van GH overmaat door acromegale patiºnten te
verdelen in well- controlled en genezen patiºnten. Met behulp van
nieuwere technieken om diastolische dysfunctie vast te stellen werd
bewezen dat de patiºnten die volgens de huidige criteria, met behulp
van medicatie geen persisterende ziekte zouden moeten hebben, nog
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steeds actieve ziekte hadden. De patiºnten hadden verder geen andere
klinische symptomen, en de uiteindelijke klinische relevantie is op dit
moment nog onduidelijk.
De observaties in hoofdstuk 2 en 3 tonen aan dat de standaard benadering
van een internist, gebaseerd op medische voorgeschiedenis en anamnese,
lichamelijk onderzoek en de juiste diagnostische test(s), falen bij
acromegalie in het detecteren van subtiele maar nog wel steeds
aanwezige ziekte met betrekking tot de biochemische parameters en
subtiele veranderingen op het hart.
Gedurende de studies beschreven in dit proefschrift, gebeurde iets
interessants. Ondanks het feit dat acromegalie al bekend is vanaf 1886,
en de wetenschap dat cardiovasculaire ziekten een belangrijke rol spelen
in de verhoogde mortaliteit en morbiditeit bij acromegalie, was het
verbazend dat er geen duidelijke documentatie was over het effect van
GH overschot op de functie van de hartkleppen. We werden
geconfronteerd met deze vraag toen enkele van onze patiºnten een
gedocumenteerde insufficiºntie hadden van de mitraal- en/of aortaklep.
Ondanks meerdere studies met echocardiografie bij acromegalie, werd
er geen relatie beschreven tussen acromegalie en hartklep insufficiºntie.
In hoofdstuk 4 hebben we de prevalentie vergeleken van
hartklepinsufficiºntie tussen acromegale patiºnten en gematchte
controles. Daarvoor ondergingen 40 acromegalen echocardiografie om
te bepalen of dat er sprake van was klep insufficiºntie in vergelijking
met 120 gezonde controles, gematcht voor leeftijd, geslacht en
bloeddruk. De prevalentie van klepinsufficiºntie was drie maal verhoogd
in de groep van acromegale patiºnten (22% vs. 7% bij de controles).
Aorta klepinsufficiºntie kwam in 20 % van de patiºnten voor vergeleken
met 4 % van de controles. Mitraal klepinsufficiºntie kwam maar in 5 %
van de gevallen voor vs 0 % bij de controles. Opvallend was dat geen
van de patiºnten met kleplijden symptomen had, of bekend was bij een
cardioloog. Toch was het kleplijden klinisch relevant, volgens de
participerende cardiologen. Een langdurigere blootstelling aan
groeihormoon overschot was geassocieerd met een verhoogde
prevalentie van kleplijden. We postuleren dat de schade die ontstaat bij
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acromegalie aan de hartkleppen irreversibel is, in tegenstelling tot een
aantal andere symptomen van acromegalie. Dit is onder andere ook
gebaseerd op het histologisch onderzoek op een van de hartkleppen,
dat was verricht bij een acromegale patiºnt na een klepvervanging,
beschreven in hoofdstuk 4.
Concluderend kan er gezegd worden dat er is sprake van een hoge
prevalentie van kleplijden bij acromegale patiºnten, hetgeen samenhangt
met de duur van het overmatige groeihormoon productie. Blijkbaar heeft
de standaard benadering van de internist gefaald in het detecteren van
deze belangrijke complicatie van acromegalie in de afgelopen 120 jaar.
Daarom dienen patiºnten met actieve ziekte een echocardiografie te
ondergaan om kleplijden vast te stellen aangezien dit bij fysisch
onderzoek gemist kan worden. Het kan belangrijke consequenties
hebben voor hun behandeling.
Groeihormoon tekort
Ziekten, die de somatotrope cellen van de hypofyse beschadigen,
veroorzaken GH deficiºntie. Het syndroom van GH deficiºntie bij
volwassenen resulteert in subtiele veranderingen in fysiek welbevinden
en in biochemische parameters. Het wordt nu aanbevolen om deze
patiºnten te behandelen met recombinant groeihormoon met als doel
IGF-I concentraties te verkrijgen die liggen in het hoge-normale gebied
met het doel de kwaliteit van leven en het cardiovasculaire risico te
verbeteren. Omdat de klachten en fysieke effecten van GH deficiºntie
subtiel en aspecifiek zijn, zijn er geen goede klinische of biochemische
parameters om de behandeling met rhGH te verfijnen behoudens dan
IGF-I concentraties. Daarbij moet nog worden opgemerkt, dat er tevens
sprake is van intrinsieke imperfectie met betrekking tot fysiologische
GH vervanging. GH wordt pulsatiel gesecerneerd, hetgeen door een
dagelijkse subcutane injectie met rhGH niet kan worden nagebootst.
Sterker nog, patiºnten met hypofysaire insufficiºnties hebben vaak
meerdere endocriene insufficiºnties, waarbij de substitutie op zichzelf
weer fysiologische beperkingen heeft. Door een zo optimaal mogelijke
substitutie van deze endocriene insufficiºnties mag de kwaliteit van
leven van patiºnten met een hypofyse ziekte weliswaar verbeterd zijn,
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het blijft tot op zekere hoogte beperkt.
In hoofdstuk 5 evalueerden wij de kwaliteit van leven van patiºnten
met langdurige GH substitutie. Een breed spectrum van kwaliteit van
leven parameters werd onderzocht en vergeleken met leeftijd- en geslacht
gematchte controles. In het algemeen hadden vrouwen een meer
gestoorde kwaliteit van leven dan mannen. De GH deficiºnte vrouwelijke
patiºnten hadden problemen met fysiek functioneren en zij voelden
bovendien, dat hun functioneren was beperkt door hun fysieke en
emotionele problemen vergeleken met de controle populatie (SF-36).
Tevens was er sprake van algemene en fysieke vermoeidheid (MVI-
20). Zowel mannelijke als vrouwelijke GH deficiºnte patiºnten hadden
beide zowel problemen met het sociale functioneren, als met een
verminderde activiteit. Alleen bij de mannen was de
gezondheidsbeleving gestoord ten opzicht van controles. De resultaten
waren interessant aangezien de meeste patiºnten langdurig vervolgd
waren. Bovendien was er weinig inzicht bij de behandelende dokters in
de gestoorde kwaliteit van leven van onze patiºnten. Blijkbaar is de
standaard benadering van een internist onvoldoende om de kwaliteit
van leven te beoordelen, ondanks dit wel een van de doelen is van
behandeling van GH deficiºnte patiºnten.
Een aantal jaren gelden werden er positieve resultaten beschreven van
DHEA substitutie bij patiºnten met primaire bijnierinsufficiºntie. DHEA
en DHEA-S zijn vreemde steroiden. Ondanks het feit dat de concentraties
van DHEA en DHEA-S een aantal maal hoger zijn dan die van  andere
bijnierhormonen, is hun functie nog verre van opgehelderd. Tot nu toe
zijn er nog geen receptoren gevonden bij de mens voor deze
bijniersteroïden. Er is gepostuleerd dat zij voorlopers zijn van actieve
steroïden die intracellulair worden geproduceerd, bijvoorbeeld de
hersenen. Door DHEA concentraties te verhogen naar fysiologische
spiegels verbeterde de kwaliteit van leven bij patiºnten met een
bijnierinsufficiºntie. Daarnaast was er een interessant epifenomeen in
de vorm van een stijging van het IGF-I gehalte.
De vraag kwam op, of de verbetering in kwaliteit van leven en de stijging
van IGF-I in relatie met elkaar stond. In hoofdstuk 5 is een dubbel
blinde cross-over studie naar de effecten van DHEA versus placebo
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beschreven bij GH deficiºnte patiºnten met een ACTH deficiºntie. De
DHEA concentraties stegen hierbij naar fysiologische niveaus. In het
algemeen ervoeren de patiºnten een duidelijke verbetering van hun
kwaliteit van leven. Toch observeerden wij, dat zij niet precies spontaan
konden aangeven wat er precies veranderd was in hun functioneren.
Daarom schiet de algemene benadering van de internist in de anamnese
tekort om subtiele veranderingen in kwaliteit van leven te detecteren,
zoals gemeten middels gedetailleerde vragenlijsten. Toch heeft ook het
gebruik van vragenlijsten zijn beperkingen. Kwaliteit van leven is iets
abstracts wat moeilijk is te bepalen en elke persoon heeft zijn/haar
verschillende interpretaties van haar/zijn kwaliteit van leven. Een ander
probleem is gerelateerd aan het bepalen van een goede controle populatie,
wat kan zorgen voor bias. Referentie gegevens uit de literatuur zijn ook
niet toepasbaar op de studie populaties. Daarom was elke patiºnt zijn/
haar eigen controle in onze studie.
Bij vrouwen was de kleine verbetering van kwaliteit van leven niet
geassocieerd met een verhoging van IGF-I concentraties. Opvallend was
dat IGF-BP3 concentraties, een belangrijk GH bindingseiwit in plasma,
niet stegen, wat betekende dat de verhoging van IGF-I concentraties
niet alleen een resultaat was van stijging van de IGF-BP3 concentraties.
Omdat alle patiºnten een gefixeerde dosis rhGH kregen kon een
verhoogde beschikbaarheid van GH ook geen verklaring zijn van de
stijging van IGF-I concentraties. We hebben alleen postmenopauzale
vrouwen onderzocht met hypopituitarisme zonder oestrogeen substitutie,
terwijl de mannen allemaal testosteron substitutie kregen. We speculeren
dat het verschil van hormonale substitutie tussen mannen en vrouwen
en/of het geslacht mogelijk de oorzaak is van het verschil in resultaat
gevonden bij DHEA substitutie op IGF-I. Er dient worden opgemerkt
dat mannen boven de 50 jaar nog steeds testosteron substitutie krijgen
terwijl bij vrouwen dit niet standaard wordt gegeven.
In hoofdstuk 6 worden de gegevens gepresenteerd van een prospectieve,
gerandomiseerde studie naar de effecten van GH substitutie in patiºnten
met ischemisch hartfalen. Het basis concept gedistilleerd uit nadere
studies was dat cardiomyocyten GH en IGF-I receptoren hebben en dat
155
Discussie en samenvatting
GH behandeling mogelijk een positieve verandering zo kunnen geven
bij patiºnten met een gestoorde hartfunctie. De patiºnten kregen rhGH
in een dosis gelijk aan die van GH deficiºnte patiºnten. Helaas werd er
geen effect waargenomen op hartfunctie gemeten na 6 maanden van
behandeling. Deze gerandomiseerde studie toonde aan dat rhGH
substitutie in patiºnten met verder normale endocriene functie geen
voordeel heeft ten aanzien van hun hartfunctie. De vraag kwam op of
het initiºle idee om dit soort studies te doen in deze groep van patiºnten
zonder endocriene dysfunctie wel helemaal solide was. In begin van de
jaren negentig toonden observationele studies met rhGH behandeling
in kleine groepen van patiºnten met hartfalen positieve veranderingen
aan op de linker ventrikel massa en de systolische functie. Bovendien
werd de suggestie gewekt, dat deze patiºnten een gestoorde GH/IGF-I
as hadden gezien hun lagere IGF-I concentraties. Echter, een grote studie
op een intensive care toonde aan dat GH substitutie, weliswaar in
suprafysiologische doseringen, leidde tot een verhoogde mortaliteit. In
dit licht kan er een parallel gemaakt worden naar de effecten van
schildklierhormoon in patiºnten met non-thyroidal illness. In deze
patiºnten is tot nu toe geen consistent positief klinisch effect beschreven
van schildklierhormoon substitutie. De veranderingen in hormonale
concentraties op basis van niet-endocriene ziekte reflecteert vaak de
adaptieve capaciteit van het menselijk lichaam. Voordat men dan ook
intervenieert met het menselijk lichaam, moet men de onderliggende
pathofysiologische mechanismen begrijpen. Het is interessant dat alle
studies met rhGH bij hartfalen waren gebaseerd op een ongecontroleerde
studie en dat uiteindelijk de hype werd afgesloten met prospectieve
gerandomiseerde studies.
Concluderende opmerkingen
Internisten gebruiken een standaard benadering om te symptomen van
patiºnten te evalueren, aangevuld met diagnostische tests, om een
diagnose of een activiteit van een ziekte vast te stellen en het effect van
een behandeling te evalueren. Tegen deze achtergrond hebben de
klinische syndromen van GH overschot en -tekort enkele moeilijkheden.
Met uitzondering van de zeer lang onderkende casussen van acromegalie,
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zijn de symptomen en afwijkingen van beide syndromen subtiel en
aspecifiek. Daardoor zijn ze moeilijk te kwantificeren met klinische
parameters. De studies beschreven in dit proefschrift tonen aan, dat er
enkele tekortkomingen zijn in de standaard benaderingen van de
internist. De associatie tussen acromegalie en kleplijden is voor 120
jaar ontsnapt aan de aandacht van de dokters. Bij het vaststellen van de
ziekte activiteit en het effect van de behandeling van overmatige en
tekortschietende GH secretie, kunnen we slechts vertrouwen op
biochemische criteria. De huidige behandelingscriteria voor acromegalie
zijn gebaseerd op mortaliteit studies. Echter acromegalie patiºnten die
volgens deze criteria well-controlled zijn, hebben nog steeds subtiele
GH overactiviteit ondanks de behandeling met somatostatine analogen.
We toonden aan, dat er sprake was van biologische activiteit van deze
subtiele GH overproductie ten aanzien van het hart, aangezien er sprake
was van diastolische dysfunctie in deze groep patiºnten, wat niet
aanwezig was in de gecureerde patiºnten na transsfenoidale chirurgie.
Ook bleken er geen verschillen te zijn tussen de beide verschillende
somatostatine analogen in betrekking tot hun controle van de GH
hypersecretie.
De studies bij GH deficiºnte patiºnten toonden aan, dat onze huidige
klinische benaderingen niet in staat zijn om het effect van behandeling
ten aanzien van de kwaliteit van leven vast te stellen. Gebruikmakend
van gestructureerde vragenlijsten waren we niet in staat aan te tonen
dat er een verbetering van kwaliteit van leven plaats vindt bij GH
deficiºnte patiºnten met een secundaire bijnierinsufficiºntie door het
toevoegen van DHEA substitutie aan de behandeling. Echter de patienten
ondervonden een subjectieve positieve verandering.
Uiteindelijk, dienen we de behandeling van ziekte te baseren op solide
bewijzen van onderliggende pathofysiologische mechanismen. GH
substitutie bij personen zonder endocriene dysfunctie maar met
ischemisch hartfalen heeft geen belangrijke toegevoegde waarde.
Uiteindelijk was er geen bewijs dat GH een rol heeft in de pathofysiologie
van hartziekten in patiºnten zonder GH deficiºntie of - excess.
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Nawoord
Vele mensen hebben bijgedragen aan de tot stand koming van dit
proefschrift. Lans deze weg wil ik hen graag bedanken.
Allereerst zou ik alle patiºnten willen bedanken die hebben deelgenomen
aan alle onderzoeken. U allen heeft mij in grote mate geïnspireerd in
het verrichten van klinische onderzoek.
Ten tweede alle zusters op de verpleegpost B-4. Jullie allen zorgden
ervoor dat ik mijn thee bij jullie kon komen drinken en even kon
afblazen. Daarnaast waren jullie altijd bereid om mij op enigerlei wijze
te ondersteunen bij het onderzoek. En Astrid, onze gedachten
uitwisselingen zijn zeer waardevol geweest!
Alle verpleegkundigen en voedingassistenten van de verpleegafdeling
Endocrinologie wil ik van harte bedanken voor jullie hulp. Met name
Rens en Rietje, bedankt voor de prettige samenwerking en goede
adviezen. Uiteraard  gaat zeer speciale dank naar Ingrid Verheule. Vanaf
dag ØØn toen ik startte als beginnend assistent, was je mijn steun en
toeverlaat. Als onderzoeker was je me zeer waardevol want door jouw
organisatie talent kon ik alle onderzoekspatiºnten zonder al te veel
problemen in plannen. Zeer waardevol waren alle gesprekken die we
hebben gehad over het leven.
Hierop volgend wil ook alle studenten bedanken die hebben meewerkt
als lid van het 24 uurs ritme team. Zonder jullie was me dit niet gelukt!
Maggy, je moest de kamer delen met de studenten hoewel zij dit niet
altijd netjes achterlieten. Sorry! Marjolein Knoester dank voor alle extra
hulp aan dit proefschrift!
Alle secretaresses op de poli: sorry dat jullie de statussen altijd moesten
zoeken op mijn kamer. Gelukkig heeft de aparte archiefkast voor alle
hypofyse patiºnten jullie wat werk ontnomen. Mijn speciale dank:
Eveline de Lange, je hebt me steeds weer verbaasd met jouw zeer goede
geheugen! Dank dat er altijd wel ergens een gaatje was om me te helpen!
Geen ritmeonderzoek zou gepubliceerd zijn als Marijke Frölich, Marijke
en Joke er niet waren. Alle ritmes zijn met grote zorgvuldigheid door
jullie geanalyseerd. Ik dank jullie tevens dat ik altijd wat extra monsters
kon laten analyseren.
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Graag wil ik ook mijn dank uitspreken aan het laboratorium van de
Endocrinologie en met name Chris, Ivo, Marcel en Trea. Jullie stonden
altijd klaar om me te helpen en te adviseren hoe het ØØn en ander het
best kon worden georganiseerd.
De woensdagen met dr. Roelfsema kunnen niet onvermeld blijven.
Onder een genot koffie werd dan behalve de ontwikkelingen in het
onderzoek alles tot en aan de wereld politiek doorgenomen. Tevens
stimuleerde u mij altijd om problemen ook op een andere manier te
bekijken.
Last but not least, de secretaresses van de staf, Caroline en Marjolein,
dank voor de hulp in de laatste fase. Maar ook voor de vele gezelligheid
bij onder andere het organiseren van de afdelingsuitjes.
Nienke, als tandem waren we erg goed. Ik hoop dat we dit in de toekomst
nog lange tijd kunnen blijven doen.
Winneke en Erwin, bedankt dat ik bij jullie altijd onder genot van lekker
eten kon ontspannen.
Imke, dank voor al je steun als verzorgende huisgenoot. Een zeer speciaal
jaar samen.
Lieve Hanneke, zonder jou geduld, begrip en hulp had het allemaal wat
langer geduurd.
Lieve ouders, we hebben samen een lange weg afgelegd waar we vele
heuvels hebben moeten overwinnen en tegen vele stromingen hebben
moeten oproeien. Zonder jullie onvoorwaardelijk steun en strijdlust zou
ik nooit zo ver zijn gekomen.
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